Feeds:
Posts
Comments

Archive for the ‘Conference Coverage with Social Media’ Category

Tweets for AI and Machine Learning in Clinical Trials April 12th, 2018 hosted at Pfizer’s Innovation Research Lab in Cambridge, MA @AVIVA1950 @pharma_BI

Posted in Artificial Intelligence - General, Conference Coverage with Social Media, Regulated Clinical Trials: Design, Methods, Components and IRB related issues, tagged on April 12, 2018| Leave a Comment »

Tweets for AI and Machine Learning in Clinical Trials April 12th, 2018 hosted at Pfizer’s Innovation Research Lab in Cambridge, MA @AVIVA1950 @pharma_BI

Curator: Aviva Lev-Ari, PhD, RN

 

 

Read Full Post »

The Convergence of Medical Devices & Drugs: Advances in Drug Delivery May 3, 2018 12:00 PM – 5:00 PM, Westin Hotel, Waltham, MA

Posted in Conference Coverage with Social Media, Drug Carrier Design, Drug Delivery Platform Technology, Medical Devices R&D Investment, Medication Remote Compliance Monitoring on April 5, 2018| Leave a Comment »

The Convergence of Medical Devices & Drugs: Advances in Drug Delivery May 3, 2018 12:00 PM – 5:00 PM, Westin Hotel, Waltham, MA

Reporter: Aviva Lev-Ari, PhD, RN

Westin Waltham Boston 
70 3rd Avenue Waltham MA US 02451

Venue WebsiteGet Directions

MassBio’s second annual Medical Device Event will focus on opportunities and advances in drug delivery, including the unique developmental and regulatory challenges these products face, the many scientific advances in the space and new opportunities for funding.  Panelists will discuss innovation and commercialization strategies.

Advances in drug delivery technologies are improving the safety and efficacy of new and existing therapies. The success of many new therapies in development is contingent on the development of effective delivery systems.   Traditional drug delivery methods won’t work for some compounds and biologics.   Stability issues create challenges for storage and transport.  There are opportunities for combination drug delivery products to extend the patent life of drugs on the market.  From diffusion based polymer systems to complex delivery devices utilizing diagnostic sensors and sophisticated control systems for precise and timely delivery of life-saving agents, a diverse set of scientific and engineering disciplines are being brought to bear within this space.  However, combination products involve components that would normally be developed under different types of regulations, design criteria, and controls.  This symposium will explore many of the diverse aspects impacting drug delivery products.

This event will feature an active exhibit hall, panel discussions, a keynote speaker and networking sessions. This is an excellent opportunity for companies to reach a diverse audience that represents nearly every aspect of the life sciences industry, including academic researchers, entrepreneurs, device engineers and biopharma executives.

Clinicians will discuss the medical challenges for which drug delivery innovations have provided a unique solution.  Academic researchers will discuss scientific advances which may lead to breakthrough products.   Entrepreneurs will discuss strategies for funding new product ventures, and development issues specific to drug delivery products.  Corporate speakers will discuss the challenges across the value chain of manufacturing and selling combination products globally.  Regulatory speakers will address current thinking and approaches to drug delivery products within government agencies, both US and internationally.

SOURCE

https://www.massbio.org/events/the-convergence-of-medical-devices-and-drugs-advances-in-drug-delivery-2624?utm_campaign=med-device-18&utm_medium=email&utm_source=email-signature&utm_content=&utm_term=

Registration

12:00 pm – 12:30 pm

Opening Remarks

12:30 pm – 12:45 pm

Keynote Presentation

12:45 pm – 1:15 pm

Innovation & Development Panel

1:30 pm – 2:45 pm

Networking Break

2:45 pm – 3:15 pm

Commercialization Pathways Panel

3:15 pm – 4:30 pm

Networking Reception

4:30 pm – 5:30 pm

Speakers

  • Bob Coughlin, President & CEO, MassBio

Keynote Speaker: Michael J. Cima, Ph.D., Associate Dean of Innovation, MIT

  1. Intraperiotneal Chemotherapy needed to remove the few cells left after surgery _ delivery of drugs to a single compartment
  2. Hyperthermic Intraperiotneal Chemotherapy
  3. Tumor burden – stage 3 women ovarian cancer
  4. Extended IP drug exposure
  5. device for drug delivery to the bladder (cancer): Inflammatory bladder disease, overactive Bladder, bladder (cancer); bladder removal (radical cystectomy – residual tumor size 3 cm tumor)
  6. Local Drug delivery for stone disease in ureter
  7. Change the pharmacology and change the lesion in the bladder – lesion disappeared in a single compartment
  8. Mutation burden in Brain Cancer and in Ovarian Cancer much smaller than in Lung cancer
  9. local drug delivery to one location in the brain and the drug will be carried to the entire body – pathology of the brain leads to different disease related to the Human Brain. Treatment of hemorrhage
  10. Cervical cancer under MRI deliver drug to the tumor hypoxy of the tumor, guide the drug dosage using imaging MRI is Radiation therapy not drug therapy

PANEL 1: Product Development: Drug-Device Technology moderated by Kristina Bieker-Brady, Ph.D., Partner, McDermott Will & Emery LLP

  1. Basic research to clinical development: Drug delivery System
  • Benjamin S. Bleier, MD, FACS, FARS, Associate Professor, Director of Endoscopic Skull Base Surgery, Co-Director Center for Thyroid Eye Disease and Orbital Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School
  1. BBB – Invasive, Non-invasive, Drug modification
  2. Platform technology , Enabling technology to pass BBB Scalable technology: SAfe
  3. Nasal bleed
  4. Nasal Cavity – ENTRY point to the brain use vascularized tissue
  5. nasal mucosa more permeable that any other tissue – diffuse drugs into the brain
  6. Autologous tissue – Nasal Mucosa: Proteins Oligonucleotides,
  • Maria Palasis, President and CEO, 480 Biomedical, Inc.
  • Maria Berkman, MD, MBA, Director and Head of MedTech practice, Broadview Ventures
  • Evan Sherr
  1. Brent Buchine, Ph.D., Co-Founder and CTO, Windgap Medical, Inc.

 PANEL 2: Commercialization Challenges

Moderator: Harry Glorikian, General Partner, New Ventures Funds

  • Paul Just, PharmD, Senior Principal, Medical Device Health Economics, ICON plc
  1. VALUE (outcome achieved per $) is the currency for market ACCESS knock down barriers Care COST
  2. Physician choose product that they wish to use while providing therapy as the lowest cost
  3. Assessing Differentiating Value and Reimbursement
  4. No guidance for combination products: New method of treating patients: Drug-Device
  5. Value: Who benefits from the Value – Target stakeholders: 90 days vs 18-24 month, long term value
  • Pamela J. Weagraff, Director, MedTech Regulatory, IQVIA [Quantile merged IMS]
  1. MedTech meet BioPharma
  2. Clinical data requirements for medical devices on the increase but not not necessarily in many cases
  3. Combination Products: Microfluidics, micronization – not chemistry but features of the drug delivery device
  4. Option 1,2,3 for Combination Product Pathways: Draft Guidance –>> FINAL immediately in effect
  • Jessica Ballinger, Chief Operating Officer, Lyndra
  1. Lyndra’s Ultra-long drug release – Extended Release Oral Capsule: 7 days
  2. Dosage Form – Safety
  3. Drug delivery – material manufacturing for long term resident inside the human body
  4. Candidates: AD, Diabetes
  5. Encapsulation automated – 3 partners assembly in several int’l locations in the supply chain: complications in making tablets – three years before the launch, freeze design 1st generation, 2nd generation
  • Steven Rosenberg, Otsuka Pharmaceutical

 

Read Full Post »

Synopsis Track 7: NGS in Real Time @pharma_BI 2018 CHI’s BioIT World conference & Expo, May 15 – 17, 2018, Boston, MA – Seaport World Trade Center

Posted in BioIT: BioInformatics, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Conference Coverage with Social Media on April 5, 2018| Leave a Comment »

Synopsis Track 7: NGS in Real Time @pharma_BI 2018 CHI’s BioIT World conference & Expo, May 15 – 17, 2018, Boston, MA – Seaport World Trade Center, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 1: Next Generation Sequencing (NGS)

Synopsis Track 7: NGS in Real Time @pharma_BI 2018 CHI’s BioIT World conference & Expo, May 15 – 17, 2018, Boston, MA – Seaport World Trade Center

http://www.bio-itworldexpo.com/

LPBI Group will cover Track 7: NGS in Real Time

@pharma_BI

@AVIVA1950

Aviva Lev-Ari, PhD, RN will be in attendance

 

 

 

 

Conference Programs
Industry Awards
Hackathon
Hall Pass
About the Event
Event Brochures
Videos and Photos
Bridge to Pop Health East

 

 

2018 Plenary Keynote Speakers

Mark BoguskiMark Boguski, MD, PhD
Executive Vice President and Chief Medical Officer, Liberty BioSecurity
tanya cashTanya Cashorali
Founder, TCB Analytics 
John ReyndersJohn Reynders, PhD
Vice President, Data Sciences, Genomics, and Bioinformatics, Alexion Pharmaceuticals, Inc.

 

Jerald SchindlerJerald Schindler, DrPH
Vice President, Biostatistics, Merck Research Laboratories (Retired)
Yu LihuaLihua Yu, PhD
Chief Data Science Officer, H3 Biomedicine

Join the Community at Bio-IT World Conference & Expo

Conference
Attendance

Advance Registration Savings
End Friday, April 6

REGISTER NOW

Exhibit Hall
& Keynote Pass

Available for Free
Until May 4

REGISTER NOW

Sponsor & Exhibit
Opportunities

View Prospectus
& Attendee Breakdown

VIEW DETAILS

Press
Participation

Hear Industry Updates
Straight from the Bio-IT Innovators

LEARN MORE

 

 

 

TUESDAY, MAY 15

7:00 am Workshop Registration Open and Morning Coffee

 

8:00 – 11:30 Recommended Morning Pre-Conference Workshops*

W4. Introduction to Scalable and Reproducible RNA-Seq Data Processing, Analysis, and Result Reporting Using AWS, R, knitr, and LaTex

12:30 – 4:00 pm Recommended Afternoon Pre-Conference Workshops*

W13. Leveraging Cloud Technologies to Enable Large-Scale Integration of Human Genome and Clinical Outcomes Data

* Separate registration required.

2:00 – 6:30 Main Conference Registration Open

4:00 PLENARY KEYNOTE SESSION

Click here for detailed information

5:00 – 7:00 Welcome Reception in the Exhibit Hall with Poster Viewing

WEDNESDAY, MAY 16

7:00 am Registration Open and Morning Coffee

8:00 PLENARY KEYNOTE SESSION

Click here for detailed information

9:45 Coffee Break in the Exhibit Hall with Poster Viewing

LARGE-SCALE RNA-SEQ AND GENE EXPRESSION VARIABILITY

10:50 Chairperson’s Remarks

11:00 KEYNOTE PRESENTATION: RNA-Seq X: Look Back and Look Ahead

Shanrong Zhao, PhD, Director, Computational Biology and Bioinformatics, Pfizer, Inc.

Since Dr. Mortazavi published his groundbreaking research entitled “Mapping and Quantifying Mammalian Transcriptomes by RNA-Seq” in Nature Methods in 2008, RNA-seq has evolved rapidly and revolutionized biological research, drug development and clinical diagnostics. 2018 is the 10-year anniversary of RNA-seq, and it’s the right time to look back and look forward.

11:30 LCA: A Robust and Scalable Algorithm to Reveal Subtle Diversity in Large-Scale Single-Cell RNA Sequencing Data

Xiang Chen, PhD, Assistant Member, Department of Computational Biology, St. Jude Children’s Research Hospital

We developed Latent Cellular Analysis (LCA), a machine learning based single-cell RNA sequencing (scRNA-seq) analytical pipeline that combines similarity measurement by latent cellular states and a graph based clustering algorithm featuring dual-space model search for both the optimal number of subpopulations and the informative cellular states distinguishing them. LCA has proved to be robust, accurate and powerful by comparison to multiple state-of-the-art computational methods on large-scale real and simulated scRNA-seq data.

12:00 pm Presentation to be Announced

 

12:15 RSEQREP: An Open-Source Cloud-Enabled Framework for Reproducible RNA-Seq Data Processing, Analysis & Result Reporting

Johannes Goll, Director, Bioinformatics, The Emmes Corporation

RSEQREP (RNA-Seq Reports) is a new open-source cloud-enabled framework that allows researchers to execute start-to-end RNA-Seq analysis to characterize transcriptomics changes in human cells following treatment. It outputs dynamically generated reports using R and LaTeX. We provide results for a published RNA-Seq study to characterize transcriptomics changes following influenza vaccination.

12:30 Session Break

WuXi_Nextcode_notagline12:40 Luncheon Presentation I: Querying of 100k Genomes Using Google Cloud

Hákon Gudbjartsson, PhD, Chief Informatics Officer, WuXi NextCODE

Hákon Gudbjartsson will demonstrate the power of the GOR database in real time. GORdb is used to organize, mine and share massive genome datasets, providing a global architecture for the largest precision medicine efforts worldwide. It’s designed to enable fast, computationally-efficient use of sequence data, and allows for the query and application of data in the context of reference sets.

1:10 Luncheon Presentation II (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:40 Session Break

OPTIMIZING GENE BASES WITH CODON USAGE

1:50 Chairperson’s Remarks

Leonard Lipovich, PhD, Associate Professor with Tenure, Center for Molecular Medicine and Genetics, Wayne State University

1:55 Analysis of Codon Optimized Therapeutic Proteins Using Ribosome Profiling

Chava Kimchi-Sarfaty, PhD, Research Chemist, Principal Investigator, OTAT Acting Deputy Associate Director for Research, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, FDA | CBER | OTAT

Codon optimization is a genetic engineering technique used to improve the yield of recombinant therapeutic proteins. Despite being used ubiquitously to increase protein expression, codon optimization requires widespread substitution of synonymous codons across the native expression sequence. This degree of genetic manipulation can carry consequences, including altered conformation of the recombinant product. These unforeseen modifications can have impacts on protein function and health outcomes, and are of high regulatory importance. To study these techniques, we have used ribosome profiling, a technique used to characterize the translation pattern of the ribosome across the mRNA transcript. In this technique, actively translating ribosomes are cross‐linked to mRNA and is followed by nuclease digestion of mRNA not protected by a ribosome, generating short mRNA fragments (called “ribosome footprints”). These fragments are sequenced and aligned to generate a differential coverage map across portions of the transcript. This technique provides insight into the relative translation efficiency in a given area of the transcript. We have analyzed the ribosome profiling data for relationships to codon usage. By identifying regions of differential ribosome profiling patterns between wild type and codon optimized transcripts, we aim to create a method of selecting regions to leave unmodified, allowing recombinant proteins to benefit from increased expression while maintaining the integrity and safety of the protein product. Codon optimization as a technique relies heavily on accurate codon usage statistics of the organism in question, to identify rare codons to be replaced with common codons for an increase in translation efficiency. However, previous databases containing this information were either outdated or limited in scope. To address this gap in knowledge, we constructed a new database containing codon usage tables for all the species in GenBank and RefSeq. We designed a program in Python to download, parse, and organize all the sequence data available in these two repositories, and in Javascript designed an accessible web portal available to the public to query the new database. The new HIVE‐CUTs database contains substantially more organisms and coding sequence data and is a dramatic improvement upon prior databases. This tool will aid in the effective implementation of codon optimization techniques and other areas of recombinant protein design.

  1. FDA approved 2011-2017 – Therapeutic Proteins by Drug Class: i.e., Oncology , Hematology
  2. Effort on Gene therapy is primarily in Cancer Disease
  3. Factor 9 and Hemophillia B
  4. Codon Optimization to increase Protein expression TECHNIQUES:
  5. Transcription
  6. mRNA
  7. Codon Usage Database – Tables open to the public -9606 (Homo Sapient)
  8. Evaluation of Codon Optimized Factor 9 – Altered Protein Structure Binding Affinity, protein folding
  9. Riboson profile: Protected Profile 20-22 or 24-27 nucleotides [PCR Sequence] Sites: A, P, E
  10. Analysis of Ribosome Profiling Data: Correlations F9 and ACTB and GAPDH – each against Codon Optimizer
  11. In Silico: translation kinetics based solely on calculated codon usage frequency
  12. CONCLUSION:
  • Ribosomal profiling data do not correlate with codon Optimization
  • Genetically engineered therapeutics – benefit from Codon Optimization

 

 

2:25 Multidimensional Global Proteogenomics Identifies Persistent Ribosomal In-Frame Mis-Translation of Stop Codons as Amino Acids in Multiple Open Reading Frames from a Human Breast Cancer Long Non-Coding RNA

Leonard Lipovich, PhD, Associate Professor with Tenure, Center for Molecular Medicine and Genetics, Wayne State University

Two-thirds of the ~60,000 human genes (www.gencodegenes.org) do not encode known proteins, and aside from long non-coding RNA (lncRNA) genes with recently characterized functions, the possibility that these poorly understood genes’ transcripts serve as de-facto unconventional messenger RNAs has not been formally excluded. Our group was the first to use direct evidence from protein mass spectrometry, preceding efforts that employed indirect evidence from ribosome profiling, to demonstrate that specific lncRNAs are recurrently and nonrandomly translated in human cells (Bánfai et al 2012, Genome Research 22:1646-1657). In our current study, we integrated RNAseq, ribosome profiling, and mass spectrometry to globally assess lncRNA translation in human estrogen receptor alpha positive MCF7 breast cancer cells. We identified 27 peptides, mapping to multiple sense-strand open reading frames (ORFs) of the lncRNA gene MMP24-AS1, united by a novel and highly unconventional property: the existence of these peptides can only be explained by stop-to-nonstop in-frame replacements of specific UAG and UGA (but not UAA) stop codons by amino acids. This result, validated by the absence of any genomic mutations, polymorphisms, and RNA editing events in genomic and cDNA targeted resequencing, represents an unprecedented apparent gene-specific violation of the Genetic Code in human breast cancer cells, and hints at a new mechanism enhancing the combinatorial complexity of the cancer proteome.
[Note 1: This work has been funded in its entirety by the NIH Director’s New Innovator Award 1DP2-CA196375 to LL.]
[Note 2: This project encompasses collaborations. A full listing of co-authors will be shown during the talk.]

  • LncRNA
  • ENCODE –
  • WG 6-frame tRanslation + mass spectrometric data {mass specriptom] = empirical redefinition of the genomic sequencing field
  • MMP24 maps – Breast Cancer
  • Mechanism: MisTranslation – Translation Infidelity: why are only UAG and UGA, never UAA, reference-genome stop codons are affected

 

2:55 CO-PRESENTATION: Workflow Optimization for NGS Discovery – How to Drive BIX Insights

Jack DiGiovanna, PhD, General Manager, NGS Applications and Services, Seven Bridges Genomics (->2009) 250 CS

Isaac M. Neuhaus, PhD, Director, Computational Genomics, Bristol Myers Squibb

  • Predict immuno-oncoogy outcomes
  • Biomarkers
  • Microsatellite Instability (MSI) – short tanden repeats of 1 to 6 base-pairs: Detections of MSI mutations in somatic variants, Profiling
  • Whole Exome gene data
  • Companion diagnostics
  • Colorectal adenocarcinomas with MSI status
  • Validating predictions
  • Tumor Heterogeneity: Clones have different potentials to metastasize
  • Heterogeneity (purity) work flow & Validation – Variant Allele Frequency
  • MSI sensor score: Benchmarking MSIsensor vs Tumor Purity
  • Clinical MSI data

 

3:25 Refreshment Break in the Exhibit Hall with Poster Viewing

NGS DATA ANALYSIS, INTEGRATION, INTERPRETATION, AND VISUALIZATION

4:00 Variant Query Tool: Drag & Drop for a Scalable, Server-Less, Web UI to Querying Annotated Variants

William Van Etten, Senior Scientific Consultant, BioTeam

It’s a challenge to build an environment that provides real-time querying of reads and annotated variants for genomics research, requiring significant human and computational resources. Whether tens or thousands of genomes, the barrier to entry can be high for the biologists/geneticist, who might not also be computer scientist. BioTeam has developed a simple tool that leverages several AWS services (S3, Athena, Lambda, Cognito, IAM, CloudWatch) to enable a biologists/geneticist to drag & drop VCF and BAM files onto an S3 bucket, then point their web browser at this bucket, to provide a scalable, server-less, web UI to querying the reads and annotated variants within these files. We aim to demonstrate, explain, and promote what we’ve learned from this proof of concept software development in the hope that others might benefit from our experience.

http://vqt.bioteam.net

  • Amazon Athena API Introduced – Variant Query Tool – Server-less

 

 4:30 Building a GXP Validated Platform for NGS Analysis Pipelines

Anthony Rowe, PhD, Business Technology Leader, R&D IT, Janssen R&D LLC

An NGS applications approach the clinic the bioinformatics pipelines used to analyze the data have to be validated to demonstrate their correctness. This talk will present Janssen approach to deploying validated NGS applications with specific focus in microbiome metagnomics.

  • IBD: UlcerativeColitis  (UC), Crohn’s DIsease (CD)
  • $11Bil – $28Billion – Cost burden in Health Care systems
  • J&J and Vedanta announced a collaboration DNAnexus 
  • Microbiome based approach for IBD: Gut Dysbiosis, beneficial microbes symbionts, Pathogenesis
  • Jeanssen developing a new platform for DIsease therapy
  • How to analyze microbiome data as drug?
  • Stelara Biotherapeutics – 27 microbes
  • PK PD of antigen therapy
  • Biotherapeutic product like VE202 –
  • Can VE202 be detected in stool
  • Real Time NGS – The Clinical Novel NSG  for Clinical Trials – Emerging Science meets Regulated Science
  • Emerging Science: Novel NGS Informatics
  • Tool Box for Microbiome: Biomathematicians carried workflow to Clinical Trials
  • Computational workflow: Step 1: alienment 1,2,3,4
  • 7 samples 4 tools: Run Time cost result quality
  • Quality Control: for Clinical NGS Platform:Manufacturing, Software QA,
  • current system Overview: sequencing Vendors prtnerships
  • Establish scientific ladscape and a structured drug development process

Sapio Sciences

 

5:00 LIMS or ELN, Which Do You Need? [Electronic Lab Notebook]

Kevin Cramer, CEO, Sapio Sciences (->2007)

Both Biotech and Pharma need Laboratory Information Management (LIMS) and Electronic Lab Notebook (ELN) capabilities. Sapio has eliminated the barriers between these two product areas by leveraging its more than decade of unique experience offering both LIMS and ELN solutions and combining the key features of each solution into one, best of breed, product: Exemplar ELN Pro.

  • Configurable data model for LIMS Platform
  • LIMS 1.0 Configure Data Model
  • LIMS 2.0 Workflow enginw for tracking complex processes
  • NGS – 2008 Celexa,
  • ELN – 2015 Exemplar support ad Hoc experimentation, clean sheet design
  1. create RQS for Samples
  2. Assign processes
  3. Track progres
  4. register Samples
  5. Register plates Aliquoting Define Storage
  6. Graphical Assignment
  7. register consumables
  • ELN: Spreadsheets, Office Integration, Drag & Drop experiment items, Curve fitting, R Stat, Charting/visualization
  • Author/witness/Reviewer/Approver Accept/reject attach instrument design
  • ELN, LIMS, ELN Pro[fessional]
  • ELN Pro: ELN plus LIMS properties
  • Exemplar ELN Pro: storage mgm

Sapio Sciences – Exemplar ELN Pro

  • Integrate collaboration,charting tools
  • global repository
  • Chemaxon Integration
  • Prebuilt NGS pipelines out of the box

 

 

5:15 Sponsored Presentation (Opportunity Available)

5:30 Best of Show Awards Reception in the Exhibit Hall with Poster Viewing

7:00 – 10:00 Bio-IT World After Hours @Lawn on D

THURSDAY, MAY 17

7:30 am Registration Open and Morning Coffee

8:00 PLENARY KEYNOTE SESSION & AWARDS PROGRAM

Click here for detailed information

9:45 Coffee Break in the Exhibit Hall and Poster Competition Winners Announced

 

APPLICATION OF NGS TO ONCOLOGY, IMMUNOLOGY, DIAGNOSTICS, AND THERAPEUTIC DEVELOPMENT

10:30 Chairperson’s Remarks, Bruce Press, EVP Seven Bridges Genomics

10:40 Instantiating a Single Point of Truth for Genomic Reference Data

David Herzig, Scientist, Research Informatics, Roche Pharmaceuticals

This talk will exemplify how expression and mutation data were made actionable by consolidating a scattered landscape of genomic reference data into a real SPoT.

  • Common System Landscapes
  1. Data Sources
  2. Silo Solutions
  3. API
  4. Consumers: Bioinformatics, Data Science, JBrowser
  • Single Source of Truth
  1. Moving away from Silo solutions
  2. Roche Data Commons

Physical HW

File SYstem & Workflow

Single Point of Truth SSOT

Integration Data Mart

UI

All data goes into Data Storage API as input and Output from the data storage

Evaluation

  • inhouse development
  • customization of open source
  • Ensembl
  1. Genomics Reference Data manu species
  2. Multi species DB [stable ID] MySQL DB is been used
  3. API & SW: REST, Tools, Web Code
  4. Modules – Variation, Funcgen, other features CORE – genome annotation
  5. SOLUTION – 150 hours = Homo-sapiens Variation is the most time consuming Ensebl REST API Endpoints
  6. Customization: NCBI: DOwnload, Unzip data – Import data – Ensembl PERL Script goes into SPoT (SSoT)
  7. Into CORE  – only species of interestLoading Log – UPDATE META TABLE (Roche Data from BioInformatics Dept)
  8. SSOT & Arvados – 2 updates a year, 5 versions are available in parallel: Portal Page, latest version: http://genomes.roce.com:3091 http://genomes.roche.com/latest 
  9. USE CASES: Comparative Genomics

 

11:10 A Network-Based Approach to Understanding Drug Toxicity

Yue Webster, PhD, Principal Research Scientist, Informatics Capabilities, Research IT, Eli Lilly and Company

Despite investment in toxicogenomics, nonclinical safety studies are still used to predict clinical liabilities for new drug candidates. Network-based approaches for genomic analysis help overcome challenges with whole-genome transcriptional profiling using limited numbers of treatments for phenotypes of interest. Herein, we apply co-expression network analysis to safety assessment using rat liver gene expression data to define 415 modules, exhibiting unique transcriptional control, organized in a visual representation of the transcriptome. Compared to gene-level analysis alone, the network approach identifies significantly more phenotype-gene associations, including established and novel biomarkers of liver injury.

  • Phase III Clinical Trials fail due to Drug Toxicity – TXG – MAP
  • Food preservative BHA
  • antibiotic TB patient Trecator – like Tunicamycin
  • blood thinner – Ticlid
  • n-dimensional problem space for Toxicity:Gene Expression COmplexity DYnamic COmplexity, pathophysiology complexity
  • TRANSLATION: from Animal to Human Clinical Trials – Failure of Clinical Trial equals to failure of the TRANSLATION
  • Modules in DNA and RNA
  • Protein structure
  • Reduce dimensionality of the information space
  • Changes of patterns – risk assessment of the confidence in translation
  • Gene vs System-level View – Tunicamycin – image TXG – MAP = unsupervised approach to convert a table of data into ONE image
  • How to build TXG – MAP: Genotype and Phenotype – for Predictions of Untargeted Effects, recomendations
  1. Data Input
  2. Training set – DrugMatrix
  3. Algorithm – 415 co-expression module
  4. Interpretation (Gene ontology)
  • use TXG – MAP for adaptive response: Measure changes in Biological processes usinf eigengene scores
  • TXG – MAP to compare Treatments: Apoptosis post treatment with Tunicamycin Red Induced expression Green supressed expression
  • Hypetrophy caused by antibiotic Tunicamycin
  • Building TXG – MAP – for sharing with Scientific Community across species to be used in Translation Research for preservation across cell lines, across species and for translation to Humans

11:40 Michael Rusch , Dir Bioinformatics, St. Jude Cloud

  • 2017 Genomic Test is ORDERABLE >400 patients as of May 2018
  • 300 approved access requests globally – PCGP Data Sharing – 8 attempts to download have failed once
  • Solution: 2015 Cloud: Secure, sustainable, expandable
  • SW development Partner DNAnexus on Microsoft ADURE in 2017, St.Jude CLoud
  • 3000 pediatric cancer survivors – Optimize therapy to improve quality of life
  • Simple Data Access Procedure : data securely into private cloud
  • Gene fusions – Turnaround Time Challenge – Assay – 42 days – Leukemia RNA Seq workflow 15 days to get seq done
  • Cost $5-$10 per sample running 5-8 days seq, manual Review and Reporting 20 Minutes
  • most runs completed in 12 hours
  • Variant annotation, pathogenicity: Germ line Mutations and Pediatric Cancer NEJM, Journal Pediatric Oncology
  • Recan PIE – Pathogenicity Information Exchange (PIE) for SNV/Indel Classification
  • Results overview Variant page: Gene info Protein Paint, Gene ingo
  • damage prediction algorithm – ACMG classification Tool: Variant page
  • 100 Registered users
  • 425 jobs
  • 340,000 variants
  • VisualizationProtein paint, PCGP Mutation: SOmatic and Germ line Pathogenic and Likely Pathogenic Variants

https://stjude.cloud

 

11:40 Sponsored Presentation (Opportunity Available)

12:10 pm Session Break

12:20 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:20 Dessert Refreshment Break in the Exhibit Hall with Poster Viewing

DATA MINING FOR DISEASE CLASSIFICATION – CITYVIEW I

1:55 Chairperson’s Remarks

John Methot, Director, Health Informatics Architecture, Dana-Farber Cancer Institute

2:00 Disease Classification in the Era of Data-Intensive Medicine

Kanix Wang, PhD, Research Professional, Booth School of Business, Institute for Genomics & Systems Biology, University of Chicago

We used insurance claims for over one-third of the U.S. population to create a subset of 128,989 families (481,657 unique individuals). Using these data, we estimated the heritability and familial environmental patterns of 149 diseases. We then computed the environmental and genetic disease classifications for a set of 29 complex diseases after inferring their pairwise genetic and environmental correlations.

2:30 Enviro-Geno-Pheno State Approach and State-Based Biomarkers for Differentiation, Prognosis, Subtypes, and Staging

Lei Xu, PhD, Director, Centre for Cognitive Machines and Computational Health; Zhiyuan Chair Professor, Department of Computer Science and Engineering, Shanghai Jiao Tong University

In the joint space of geno-measures, pheno-measures, and enviro-measures, one point represents a bio-system behavior and a subset of points that locate adjacently and share a common system status represents a ‘state’. The system is characterized by such states learned from samples. This enviro-geno-pheno state is considered a biomarker, indicating ‘health/normal’ versus ‘risk/abnormal’ together with its associated enviro-geno-pheno condition.

3:00 PANEL DISCUSSION: Can We Improve Breast Cancer Patient Outcomes through Artificial Intelligence?

Maya Said, ScD, President & CEO, Outcomes4me, Inc. (Moderator)

Panelists:
Regina Barzilay, PhD, MacArthur Fellow and Delta Electronics Professor, Massachusetts Institute of Technology (MIT) Department of Electrical Engineering and Computer Science; Member, Computer Science and Artificial Intelligence Laboratory, MIT

Kevin Hughes, MD, Co-Director, Avon Breast Evaluation Program, Massachusetts General Hospital; Associate Professor of Surgery, Harvard Medical School; Medical Director, Bermuda Cancer Genetics Risk Assessment Clinic

Newly diagnosed cancer patients attempting to understand their treatment options face the overwhelming task of filtering an information deluge, much of which is irrelevant, outdated and occasionally inaccurate. Additionally, matching their diagnosis to best-in-class treatments or potential clinical trials, while simultaneously learning to navigate an extremely complex healthcare system is daunting, even for the most highly trained physicians. We will explore various platforms aimed at improving patient outcomes by leveraging technology to help educate, track, and connect patients with personalized resources while simultaneously working to improve the care continuum and the development of new treatments. We will explore the nexus of healthcare networks and their IT systems, clinical decision-making and delivery, R&D, and patients, for whom we all create our innovation solutions. Attendees will be interested to understand how various groups are working to increase value across the entire system by bringing laboratory, clinical and pharmaceutical science, real-world evidence and patient-reported data together with technology and artificial intelligence to solve health challenges. These approaches offer the opportunity to generate deeper insights into how therapies perform in the real world and harness that understanding to improve efficiency, effectiveness, value, and ultimately, patient care.

  • Targeted Therapy in Breast Cancer more than another diseases

4:00 Conference Adjourns

Download Brochure | Workshops

SOURCE

http://www.bio-itworldexpo.com/next-gen-sequencing-informatics/

Read Full Post »

Synopsis for AI & Machine Learning in Clinical Trials, APRIL 12, 2018 PFIZER INNOVATION RESEARCH LAB – CAMBRIDGE, MA

Posted in Conference Coverage with Social Media, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Regulated Clinical Trials: Design, Methods, Components and IRB related issues on April 2, 2018| Leave a Comment »

Synopsis for AI & Machine Learning in Clinical Trials, APRIL 12, 2018 PFIZER INNOVATION RESEARCH LAB – CAMBRIDGE, MA

Reporter: Aviva Lev-Ari, PhD, RN

Recap Book

http://viewer.zmags.com/publication/9d58c338#/9d58c338/30

 

Aviva Lev-Ari, PhD, RN, Director and Founder of  LPBI Group, will attend and cover in Real Time the Conference 

@pharma_BI

@AVIVA1950

  • Tweets for AI and Machine Learning in Clinical Trials April 12th, 2018 hosted at Pfizer’s Innovation Research Lab in Cambridge, MA @AVIVA1950 @pharma_BI

https://pharmaceuticalintelligence.com/2018/04/12/tweets-for-ai-and-machine-learning-in-clinical-trials-april-12th-2018-hosted-at-pfizers-innovation-research-lab-in-cambridge-ma-aviva1950-pharma_bi/

About Aviva Lev-Ari, PhD, RN and LPBI Group

 

 

AI and Machine Learning in Clinical Trials

April 12th, 2018 hosted at Pfizer’s Innovation Research Lab in Cambridge, MA

1 Portland St, Cambridge, MA 02139

With case studies from Pfizer, Novartis, Merck, AstraZeneca, MIT, Takeda, Sanofi & more, you will not
want to miss the latest in leveraging AI and Machine Learning in Clinical Trials.

#Pfizer #Merck #Sanofi #AstraZeneca #Novartis #Takeda #BMS #Biogen #GSK #MIT #Medable #Saama #RapidMiner

100+ innovators, data scientists, informatics, senior clinical trials execs & tech experts will convene to
discuss advances in artificial intelligence, machine learning, & clinical study data analytics.

Faculty of Advisors and Speakers:

Dan Karlin, Head of Digital Medical, Informatics, Regulatory Strategy, Pfizer
Joseph Lehar, Exec. Dir, Computational Biology, Merck
David Tester, Head, Data Sciences & Engineering, Chief Data Office, Sanofi
Bhaskar Dutta, Principal Scientist, Advanced Analytics Center, AstraZeneca
Jonas Dorn, Project Manager, Digital Health, Novartis
Jyoti Shah, Assoc. Dir, Data Development, Merck
Raj Bandaru, Sr. Director, Data Sciences Strategy, Sanofi
Ronald Dorenbos, Assoc. Dir, Materials Innovation, Takeda
Zeshan Farooqui, Sr. Clinical Site Manager, BMS
Shwen Gwee, Head, Digital Strategy, Global Clinical Ops, Biogen
Munther Baara, Head, New Clinical Paradigm, Pfizer
Shyamal Patel, Sr. Manager, PfIRe Lab, Pfizer
Bill Tobia, Lead Clinical Research Instructor, GSK
Regina Barzilay, Delta Electronics Professor, MIT
Amir Lahav, Digital Innovation Lead, Pfizer
Michelle Longmire, CEO, Medable
Karim Damji, SVP Product and Marketing, Saama
Malai Sankarasubbu, VP, AI Innovation, Saama
Ingo Mierswa, Founder/President, RapidMiner

You can take a look at the latest agenda here: http://panagorapharma.com/ai/schedule/

You can register at the following link using the promo code BOSTONBIOTECH25 for 25% off
registrations: https://panagorapharma.com/ai/registration/

If you have any other questions, you can reach out to the organizer:

Doug Lavender
CoFounder
PanAgora Pharma
Doug@panagoraconferences.com
Phone: 203-253- 6401

 

CORE THEMES:

1. An Exploration of Machine Learning for Clinical Study Data
2. Natural Language Processing (NLP) for Patient Voice Analysis via Social Channels
3. Machine Learning and Artificial Intelligence for Recruitment
4. The Potential of Machine Learning and AI for Adverse Event Identification
5. Real-time Patient Data Analysis

AGENDA for Thursday, April 12th, 2018

8:00 – 9:00 am Conference Registration Open in Pfizer Lobby – 1 Portland Street, Cambridge, MA

9:00 – 9:10 am Opening Remarks from Conference Chairman

Robert “Joe” Mather, Executive Director, Head of Digital Collaborations, Pfizer

9:10 – 9:50 am KEYNOTE PANEL: AI & ML to Support Clinical Trials – Where do we begin?
The internet of things, mHealth, wearable and sensor-enabled devices present an
unprecedented opportunity for accelerated data collection. What does it mean for life
sciences – are we prepared to handle the influx of data, and create valuable visibility to
accelerate trials? Where should we start? What are the best current applications? How can
we leverage AI and Machine Learning for Adverse Event Identification?

David Tester, Head, Data Science & Engineering, Chief Data Office, Sanofi

  • Do exploratory AI & ML outside the context of Clinical Trials 1st

Joseph Lehar, Executive Director, Computational Biology, Merck

  • Oncology – images of response to treatment are complex, Pathology is assisted by AI
  • AI can assist in cell classification
  • Biggest opportunity of AI %& ML in Immunology, use non invasive medium even behavioral indicators
  • Informed Consent in Clinical Trials
  • Development of AI models to avoid bias
  • Monitoring the Trials identify signals

Bhaskar Dutta, Principal Scientist, Advanced Analytics Center, AstraZeneca

  • Structure exploration in first study, signals used in second study
  • Even in Informatics groups there can be and there is resistance to acceptance of AI and ML
  • 80%-90% clean the data holistic data view integration and Privacy
  • pooling data sets across companies for benefits of sampling: Parkinson Disease case
  • Patients Voice in a Biomarker study as partners vs Patients as Customers

Moderator: Robert “Joe” Mather, Exec. Dir, Head of Digital Collaborations, Pfizer

  • Data sharing across the organization
  • How the audience feel about sharing code not only data

 

9:50 – 10:20 am CASE STUDY: Making Sense of Sensor Data: A Case Study in Data Quality Evaluation

Bhaskar Dutta, Principal Scientist, Advanced Analytics Center, AstraZeneca

  • Making sense of sensor data – 40 clinical data scientists and expanding
  • Tactical impact, Strategic build, Horizon Scanning &evaluaiton capabilities, Quantitative Solutions
  • % of Healthcare spending of GDP: LOWER THE % BY DIGITAL TECHNOLOGIES
  • Improve adherence no need of new drugs
  • 70% of Patients are interested in Monitoring their Health digitally
  • wearable sensors – will increase the quality of monitoring
  • Burden of Chronic disease: i.e., Asthma (23Millions), Diabetes (29Million)
  • COst direct and Indirect
  • Patient Needs
  • Challenging in using digital solutions: Lack of integration,
  • Values: to Patients, to HCP, Pharma: Drug discovery, Drug Cost
  • Digital-solutions Lifecycle: Pharma perspective: Need characterization, device sensor characterization,
  • at AstraZeneca: Project – iPREDICT – individualize PREdiction of DIsease Control using digital sensor Technology
  • Device Brands and their Price to Consumer: ZephyrBioPatch, Garmin Vivosmart, MS Band 2, GoBe, HealthPatch MD, BodyGardian, BioPatch
  • Usability Survey: Ease of setting up, Ease of use, 1st impression, comfort, likely to recommend
  • Data capturing: Missing, quality of recording – data quality evaluation: signal to noise ratio
  • poor compliance
  • Data Privacy – GPS data is the most PRIVATE: de-identification of IDs, GPS can generate identifiable data
  • Integration with other data streams
  • Six different Groups: Patient cnetrality, Applications Usability,
  • They are hiring in the MD area

 

10:20 – 10:50 am Using AI and Machine Learning to Improve Clinical Trials

• Clinical trial dedicated mobile apps can improve patient experience in clinical trials and
increase data collection and yield,
• Advanced analytics on patient data
§ HIPAA compliance, data collection & analysis

Michelle Longmire, CEO, Medable

  • Enabling Direct personalized medicine
  • current process: 1-5 drugs >$2Bil, 12 years
  • Apply AI in a Case study on mild cognitive impairment:
  1. Recruitment,
  2. Trial (drug efficacy)
  3. Endpoint (crude assessment)
  • AI – From Engagement to Insight:
  1. Trial Process, – identify Patients in populations before onset of disease
  2. Discovery, – Adaptive Trials
  3. Transformation – Digitome, Digital Biomarkers
  • Input: Patient reported data – to measure daily progress
  • Probabilistic condition for algorithm development
  • Input: Smartphone sensors: 6-minute walk
  • Input: Contextual data – Location, air quality, weather, disease & crime
  • Input: VOICE: Google Home, Amazon Alexa, Apple: Siri
  • Input: Devices: fitbit, Tomtom, biovation – Swiss company – 6 paramenters per second: Cognition applications
  • Bayesian Nets: Conditional probabilities
  • Deep learning: Pathern in data : Problem/data
  • Partnering with other Medical Centers

MEDABLE INSIGHT: Signature of Digitome

  • AI platform
  • Choose form anumber of Neural Networks (NN) ‘pattern’ to allow
  • Train Multiple NN, Time series Data, Visualization: View Data
  • Cerebrum Demo: Correlate patterns

10:50 – 11:10 am NETWORKING COFFEE AND REFRESHMENT BREAK

11:10 – 11:40 am CASE STUDY: Machine Learning for Clinical Study Data

Shyamal Patel, Sr. Manager, PfIRe Lab, Pfizer

SEE Digital Biomarkers Journal

  • DIGITAL biomarkers: from algorithms to Endpoints
  • Algorithms (gait speed, HR)–>> Biomarkers (Change is stat is it change in Disease stage?)–>>> Endpoints (relevant for target)
  • Wearable devices are tight coupled on body for continuous monitoring
  • smartphone: Sensor
  • connect devices
  • iPhone – Sensor packed powerhouse: Movement, Location, Context, Emotion (Camera, microphone)
  • 70% of data is unstructured: Text, image, video  – SOURCE: IBM
  • Why use AI for building digital biomarkers: AI: Data _ Answers =Rules vs classic Programming: Data + rules = Answers
  • AI enables:
  1. Learn efficintly large data sets
  2. make updates when more data becomes available
  3. Deploy at scale across platforms

DEEP Learning: automated driving, Object recognition, robotics, speech recognition

Case Study 1: Implement Heuristic algorithms (published in literature) Evaluate Performance (agreement with clinical ratings under controlled conditions) Train Machine Learning Models (Annotation as ground truth) to AI models

  • detect hand tremor – Quantify Tremor

Outcomes: 

  1. achieve significant reduction in false positive rate
  2. strong agreement with ratings provided by trained clinical raters

Case Study 2: Mining the sound signal for biomarkers

Outcomes:

  1. 85% accuracy in hackaton

Evaluating AI driven Digital Biomarkers:

Accuracy – Problem: Over fitting

Speed

Explainability – How does the model works? – understand the trade offfs

Scalability – do not be a hammer looking for a nail

 

11:40 – 12:10 pm Accelerating Clinical Trials using Natural Language Understanding

Pharma has a big text problem. Lots of useful information buried in unstructured data
formats that is difficult to use. Natural Language Understanding will help to turn what was
once unusable data into meaningful insights that can be applied to the clinical trial
development continuum. NLU engines also open up the possibility for users to have a more
interactive relationship with their vast data stores using speech or chat messaging in a
conversational experience
Come and see how we are using Natural Language Understanding to solve problems:
• Adverse events in the real world and clinical trials
• Better matched patients for on-going clinical trials
• Hidden associations from interactions between physiology, therapies, and clinical
outcomes

Karim Damji, SVP Product, Saama
Malai Sankarasubbu, VP of AI Research, Saama

  • Too many variations
  • ADE – Adverse Drug Event extraction from Biomedical Text

Data Manager: Delivers Clinical Data Analytics as a Service using Saama platform 

Implementation of dashboard: Smart Assistant for Clinical Operations:

  • Initiate a conversation over multiple natural channels of engagement
  • Identify intent and entity Need for NLU engine !!!!!
  1. Intent extractor
  2. Entity Extractor
  3. Conversation Experience (CX): One question per one answer – not a good CX

Saama: ChatBot Voice interaction

  • Rank studies on Pancreatic Cancer in ClinicalTrials.gov by Inclusion vs Exclusion Criteria
  • Entity extraction and Patinet matching for EHR Data
  1. Protein
  2. Chemical compound
  3. Organism
  4. Environment
  5. Tissue
  6. Disease/phenotype
  7. Gene Ontology Term

12:10 – 12:40 pm CASE STUDY: Bringing Digital Health and Artificial Intelligence to Merck

Merck is building up digital health capabilities to increase patient engagement, improve trial
performance, and develop clearer disease phenotypes. I will describe some efforts across
the organization in this area & provide examples of smart trials / AI collaborations underway.

Joseph Lehar, Executive Director, Computational Biology, Merck

  • Digital health innovations at Merck
  1. quantitative phyenotypes – clearer disease signals
  2. trial performance – more effective and more efficient
  3. Patient outcomes – Better ones
  4. Data analytics & Infrastructure – enabling 1,2,3
  • Smart trials: pacient-centric studies
  • Pilot studies: Smart dosing, sampling and analytics
  • at home vs at clinic
  • smart pill packs daily blood spot for PK/DNA, e-Diary
  • less expensive sampling
  • Key findings: More trials should have smart monitoring
  • Future expansion: Better, more relevant, wider: Less invasive , Apply to active clinical trials , scale up to larger populations
  • Collaborate with big Technology companies on AI
  • Flexible, scientific partnerships
  • Projects with like success sooner
  • Projects underway or being actively planned
  • Value-based models on Trials outcomes
  • Cross functional collaborations: Organizations, Projects: i.e., Oncology, Objectives

 

12:40 – 1:00 pm SINEQUA PRESENTATION

Jeff Evernham, Sinequa

evernham@sinequa.com

  • Content of the data: Expand, Link, Enrich, Improve
  • Data set Index
  • Row IndexStructured and Unstructured (Textual)
  • DIscovery: Common variables across all data sets
  • Cognitive Analytics: SEARCH, NLP, Integrated ML
  • Single study –>> Multiple Studies –> numerical variables –>> Enriched categorical variables Unstructured data

1:00 – 1:50 pm EXECUTIVE NETWORKING LUNCHEON

1:50 – 2:15 pm CASE STUDY: We want to teach a machine to think like a physician, but how do we tell how

a physician thinks?
Inter- and intra-rater variability can severely impact the data quality of our clinical trials. If we
could teach machine learning algorithms to assess patients like experienced physicians, we
would have every patient assessed the exact same way across all the sites in a clinical trial.
As a bonus, we could make these medical assessments available in underserved areas of the
world. However, how can we train a machine learning algorithm on data annotated by
humans, if we know that those human annotations are unreliable? We will present a
framework, and the journey that led us to it, that allows combining the judgments of
multiple human raters into one consensus scale and thus provide high quality ground truth,
an aspect of machine learning that doesn’t always get the attention it deserves.

Jonas Dorn, Digital Solutions Director, Novartis

  • Rater consistency is limited given by n-Raters to K-Patients – Human consistency is limited: Disease severity score assigned
  • ML –>> Scores are generated
  • What is ground truth to be considered GOOD?
  • Comparative video rating
  • Converting ranking into scores, “true Score”
  • True score + uncertainty + rater consistency – compare realization – compare realization to threshold, comes with uncertainty
  • Combine all rating by all doctores = continuous consensus score (with uncertainties) vs Coarse ratings (raw/consensus)
  • Create consistent score through comparisons
  • Conclusion: Humans are bad at absolute ratings but good at comparison
  • Comparison-based enable virtual rating

2:15 – 2:45 pm PANEL DISCUSSION: Hearing the Voice of the Patient – How Ambient Listening Devices and Artificial Intelligence Can Improve the Clinical Trial Experience

The healthcare industry, and in particular, the clinical research sector, has recently focused
its attention on achieving “patient-centricity”. Driven by the desire to better engage clinical
trial volunteers, coupled by the need to demonstrate value-added medical products, this
has become much more than the latest buzz word. However, once the trial begins, the
patient oftentimes may feel isolated in the process – quite simply, they need to ask
questions and receive answers that they can understand. Is this an opportunity to effectively & efficiently use ambient listening devices?

How can we leverage AI and Machine Learning for the detection of adverse events, using NLP and other strategies for analysis?
Amir Lahav, Digital Innovation Lead, Rare Disease Research Unit, Pfizer

  • speech technology – voice activated mechanism
  • voice recording for Ataxia Patients – for interaction with Patients
  • Accustic pattern recognition analysis of Human voice detects Asthman or CVD in Patient : voice for detection of disease: Stroke Patient,

Zeshan Farooqui, Sr. Clinical Site Manager, Bristol-Myers Squibb

Malai Sankarasubbu, VP of AI Research, Saama

  • Multiple Indexes

Moderated by: Bill Tobia, Lead Clinical Research Instructor, GSK

Voice of patient on audio technology

2:45 – 3:15 pm CASE STUDY: Clinical Data Integration from Translational Modeling Using Machine

Learning

Raj Bandaru, Sr. Director, Sr. Director, Translational Informatics, Sanofi

  • Clinical Data Integration for Translational Modeling
  • Challenges of Data Discovery Integration of Clinical Data
  • Automated Data Cataloging
  • Data DIscovery – 80% effort
  • Crawler – Bayesian machine learning – >> data Catalog (Index) –>>  Meta Data (Information) –>>> Elastic Data– >> synonyms and hierarchhical search –>. Ontologies and Access Management
  • Probabilistic model –>> no need for complete ontologies
  • self learning, self maintaining, meta data management, Data on demand, LOW of no IT support, cost a fraction of dat integration projects
  • GOAL: develop a classifier that predicts data class and relevnce to the question being asked
  • Metadata driven Risk-based De-Identification Strategy: Internal Use, External Use
  • Data Analytics Ask a question using Amazon Alexa
  • Data science and knowledge management Team

2:50 – 3:10PM Moving beyond Actigraphy: Using AI to make sense of multi-parameter wearable sensor data

Chris Economos, VP of Business Development, PhysIQ – AI for Personalized Anomaly Detection

  • Contnuous Biosensor Data +Deep Learning to Potentially DIagnose Heart Hailure Likelihood of Heart FAilure derived from Activity Alone: Heart Failure vs Normal Vs Cancer Treatment vs COPD
  • Activity + HR: Heart Failure vs Normal Vs Cancer Treatment vs COPD
  • “baseline” vs “estimates”
  • the difference is “Residuals”
  • Actual, RR, HR, Higher than Expected: Deterioration vs Improvement
  • Chris Economos, VP of Business Development, PhysIQ Case Study: Phase 3 Cardiovascular Clinical Trial: 600 patients, 97 sites, 14 countries, 9 languages 2 CROs
  • All Causes Hospitalization vs Worsening HF Hospitalization
  • Application of AI to data detection of exacerbation

3:15 – 3:35 pm NETWORKING COFFEE AND REFRESHMENT BREAK

3:35 – 4:05 pm Learning Disease Progression and Patient Stratification Models from Images and Text

 

Regina Barzilay, Delta Electronics Professor, MIT EECS, MIT Koch Institute for
Integrative Cancer Research

  • Predict recurrences, sensitivity to Treatment, LCIS – Lobar Carcinoma In-Situ
  • Enabling New Science – NLP Atypia – 7000 cases
  • Reducing Over-treatment – 87% excision are of benign tissue
  • 31% cancers were visible a year prior to cancer
  • Interpretable Neural Models
  • Multi-Task Representation Learning: Small sample size: Task “N” Tumor Size change GOALS: Correlate similar tasks

 

4:05 – 4:25 pm How AI will transform Clinical Trials

Ronald Dorenbos, Associate Director, Materials & Innovation, Takeda

  • Patient’s Perspective: AI can help patients to get better faster, present the disease
  • Future of clinical Trials: Personalization, Patients becoming the point-of-care, Adherence, Healthier Life Style
  • patient acceptance and adoption of digital health and AI are growing
  • In Pharma: SImulation Modeling, Predicting reaction to therapies Virtual Clinical Trials

 

4:25 – 5:00 pm PANEL DISCUSSION: How to make all the Data Machine Learnable?

Raj Bandaru, Sr. Director, Data Sciences Strategy, Sanofi

  • advises to use models that will signal noise vs clean the data upfront with endless effort

Jonas Dorn, Digital Solutions Director, Novartis

  • Cleaning data MUST be done before modeling
  • At present AI will not change the WOrld as fast, future of AI will move slowly

Ingo Mierswa, Founder and President, RapidMiner

  • missing data is not an excuse, it worth a chance
  • Data Engineering and Data modeling is separate in hands of two groups, optimal modeling requires one group, cooperation and validation both groups need be involved along the entire cycle
  • Support the RIGHT to own the data

Jyoti Shah, Associate Director, Data Development, Merck

  • A lot of data and high quality of Data
  • Digital technology – data collected by machine becomes part of the process
  • Patients Centers will disctate the pace of AI adoption, they want to own data

Moderated by: Munther Baara, Head, New Clinical Paradigm, Pfizer

5:00 – 6:30 pm Networking Drinks Reception / END OF CONFERENCE

SOURCE

http://panagorapharma.com/ai/schedule/

Read Full Post »

CHI’s Discovery on Target, Sheraton Boston, Sept. 25-28, 2018

Posted in Conference Coverage with Social Media, Drug Delivery Platform Technology, Drug Development Process, Drug Discovery Chemistry, Personalized and Precision Medicine & Genomic Research, Pharmaceutical Analytics, Pharmaceutical Discovery, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Informatics, Pharmaceutical R&D Investment, Pharmacodynamics and Pharmacokinetics, Pharmacogenomics, Pharmacologic toxicities on February 21, 2018| Leave a Comment »

CHI’s Discovery on Target, Sheraton Boston, Sept. 25-28, 2018

Reporter: Aviva Lev-Ari, PhD, RN

 

ANNOUNCEMENT

Leaders in Pharmaceutical Business Intelligence (LPBI) Group is a selected CHI Business Partner for Media Communication for this event as well a provider of REAL TIME PRESS COVERAGE for this cardinal event in the domain of  Drug Discovery and Drug Delivery.

Dr. Aviva Lev-Ari, PhD, RN, Editor-in-Chief, PharmaceuticalIntelligence.com  will be in attendance covering this event for the Press using Social Media via 12 Channels

LOGO of LPBI Group

Follow us on ALL our Media Communication Channels:

Channels for e-Marketing of Biotech Conferences

  • Our Journal has 1,373,977  eReaders on 1/29/2018, for All Time and 7,283 Scientific Comments

http://pharmaceuticalintelligence.com

  • Aviva’s – +6,430 BIOTECH Followers on LinkedIn

http://www.linkedin.com/in/avivalevari

  • Aviva is a Member of +60 LinkedIn Groups in Biotech related fields

https://www.linkedin.com/groups/my-groups

  • LPBI Group’s FaceBook Page

http://www.facebook.com/LeadersInPharmaceuticalBusinessIntelligence

  • LPBI Group’s Twitter Account

http://twitter.com/pharma_BI

  • LPBI Group’s Company’s Page on LinkedIn

https://www.linkedin.com/company/9325543?trk=tyah&trkInfo=clickedVertical%3Acompany%2CclickedEntityId%3A9325543%2Cidx%3A1-1-1%2CtarId%3A1439226813927%2Ctas%3ALeaders%20in%20Pharmaceutica

 

 

For UPDATES on this Cardinal Conference and for REGISTRATION, go to 

http://www.discoveryontarget.com/?utm_source=partner

 

For PROGRAMS, go to 

http://www.discoveryontarget.com/programs

September 26-27

September 27-28

September 26-27

September 27-28

September 26-27

September 27-28

September 26-27

September 27-28

September 25

What is the Role of the Editor-in-Chief at PharmaceuticalIntelligence.com 

Editor-in-Chief’s Roles and Accomplishments

1        Curation Methodology Development

Leadership we provide on curation of scientific findings in the eScientific publishing for Medical Education contents.

In Section 1, the Leadership we provide on curation of scientific findings in the eScientific publishing for Medical Education contents is demonstrated by a subset of several outstanding curations with high electronic Viewer volume. Each article included presents unique content contribution to Medical Clinical Education.

·       These articles are extracted from the list of all Journal articles with >1,000 eReaders, 4/28/2012 to 1/29/2018.

Article Title,         # of electronic Viewers,         Author(s) Name

Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?                      16,114 Larry H. Bernstein, MD, FCAP

Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) 11,606 Vivek Lal, MBBS, MD, FCIR,

Justin D. Pearlman, MD, PhD, FACC and

Aviva Lev-Ari, PhD, RN
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care

 

  5,865 Aviva Lev-Ari, PhD, RN
Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes                  1,919 Aviva Lev-Ari, PhD, RN  

 

Bystolic’s generic Nebivolol – Positive Effect on circulating Endothelial Progenitor Cells Endogenous Augmentation  1,059 Aviva Lev-Ari, PhD, RN

 

Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes  1,339 Aviva Lev-Ari, PhD, RN

 

Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination?  1,472 Aviva Lev-Ari, PhD, RN
Treatment of Refractory Hypertension via Percutaneous Renal Denervation  1,085 Aviva Lev-Ari, PhD, RN

2        Content Creation and Key Opinion Leader (KOL) Recognition

2.1     Volume of Articles in the Journal and in the 16 Volume-BioMed e-Series

Select

Aviva Lev-Ari, PhD, RN 2012pharmaceutical

3,064 Articles

·       All  (5,288)

 avivalev-ari@alum.berkeley.edu Administrator 3064

2.1     Volume of Articles in the Journal and in the 16 Volume-BioMed e-Series

1.   Volume of Articles in the Journal since Journal inception on 4/28/2012:

·       Total articles by ALL authors in Journal Archive on 1/29/2018 = 5,288

·       ALL articles/posts Authored, Curated, Reported by Aviva Lev-Ari, PhD, RN = 3,064

2.   Volume of Articles in the 16 Volume-BioMed e-Series

·    Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/10/16/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence-contributions-of-aviva-lev-ari-phd-rn/

·       LPBI Group’s Founder: Biography and Bibliographies – Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/founder/

 

2.2     Digital Presence measured by eViews: Clicks on article by Author Name

Top Authors for all days ending 2018-01-29 (Summarized)

All Time

Author Name electronic Views
Aviva Lev-Ari, PhD, RN [2012pharmaceutical]

352,153

 

Our TEAM 5,934  

 
Founder 3,257
BioMed e-Series 3,140

 

Journal PharmaceuticalIntelligence.com 2,214
About 2,054
  VISION   2,803  

 


LPBI Group		             1,201

2.3     Digital KOL Parameters

Key Opinion Leader (KOL) – Aviva Lev-Ari, PhD, RN, as Evidenced by

https://pharmaceuticalintelligence.com/2016/07/21/key-opinion-leader-kol-aviva-lev-ari-phd-rn-as-evidenced-by/

 

3        Team building: Editors and Expert, Authors, Writers

Our Team

Selection of Journal’s Chief Scientific Officer (CSO) and BioMed e-Series Content Consultant (CC): Series B, C, D, E

L.H. Bernstein, MD, FCAP

Editorial & Publication of Articles in e-Books by  Leaders in Pharmaceutical Business Intelligence:  Contributions of Larry H Bernstein, MD, FCAP

https://pharmaceuticalintelligence.com/2014/10/16/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence-contributions-of-larry-h-bernstein-md-fcap/

4        Book Title Generation and Cover Page Design

As BioMed e-Series Editor–in-Chief, I was responsible for the following functions of product design and product launch

·       16 Title creations for e-Books

·       Designed 16 Cover Pages for a 16-Volume e-Books e-Series in BioMed

·       Designed Series A eTOCs and approved of all 16 electronic Table of Contents (eTOCs), working in tandem with all the Editors of each volume and all the Author contributors of article contents in the Journal.

·       Commissioned Articles by Authors/Curators per Author’s expertise on a daily basis

 

Below, see Volume Titles and Cover Pages:

13 LIVE results for Kindle Store: “Aviva Lev-Ari”

 

 

The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures … E: Patient-Centered Medicine Book 1)

Oct 16, 2017 | Kindle eBook

by Larry H. Bernstein and Aviva Lev-Ari

$0.00

Subscribers read for free.

Read for Free

$49.00$ 49 00 to buyKindle Edition

Get it TODAY, Jan 29

Sold by: Amazon Digital Services LLC

Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2)

May 13, 2017 | Kindle eBook

by Larry H. Bernstein and Demet Sag

$0.00

Subscribers read for free.

Read for Free

$100.00$ 100 00 to buyKindle Edition

Get it TODAY, Jan 29

Sold by: Amazon Digital Services LLC

The Immune System, Stress Signaling, Infectious Diseases and Therapeutic Implications: VOLUME 2: Infectious Diseases and Therapeutics and VOLUME 3: The … (Series D: BioMedicine & Immunology)

Sep 4, 2017 | Kindle eBook

by Larry H. Bernstein and Aviva Lev-Ari

$0.00

Subscribers read for free.

Read for Free

$115.00$ 115 00 to buyKindle Edition

Get it TODAY, Jan 29

Sold by: Amazon Digital Services LLC

Perspectives on Nitric Oxide in Disease Mechanisms (Biomed e-Books Book 1)

Jun 20, 2013 | Kindle eBook

by Margaret Baker PhD and Tilda Barliya PhD

$0.00

Subscribers read for free.

Read for Free

$75.00$ 75 00 to buyKindle Edition

Get it TODAY, Jan 29

5 out of 5 stars 6

Sold by: Amazon Digital Services LLC

Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders (Series E)

Dec 9, 2017 | Kindle eBook

by Larry H. Bernstein and Aviva Lev-Ari

$0.00

Subscribers read for free.

Read for Free

$75.00$ 75 00 to buyKindle Edition

Get it TODAY, Jan 29

Sold by: Amazon Digital Services LLC

Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Nov 28, 2015 | Kindle eBook

by Justin D. Pearlman MD ME PhD MA FACC and Stephen J. Williams PhD

$0.00

Subscribers read for free.

Read for Free

$75.00$ 75 00 to buyKindle Edition

Get it TODAY, Jan 29

Sold by: Amazon Digital Services LLC

Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: The Art of Scientific & Medical Curation

Nov 29, 2015 | Kindle eBook

by Larry H. Bernstein MD FCAP and Aviva Lev-Ari PhD RN

$0.00

Subscribers read for free.

Read for Free

$75.00$ 75 00 to buyKindle Edition

Get it TODAY, Jan 29

Sold by: Amazon Digital Services LLC

Medical 3D BioPrinting – The Revolution in Medicine Technologies for Patient-centered Medicine: From R&D in Biologics to New Medical Devices (Series E: Patient-Centered Medicine Book 4)

Dec 30, 2017 | Kindle eBook

by Larry H. Bernstein and Irina Robu

$0.00

Subscribers read for free.

Read for Free

$75.00$ 75 00 to buyKindle Edition

Get it TODAY, Jan 29

Sold by: Amazon Digital Services LLC

Metabolic Genomics & Pharmaceutics (BioMedicine – Metabolomics, Immunology, Infectious Diseases Book 1)

Jul 21, 2015 | Kindle eBook

by Larry H. Bernstein MD FCAP and Prabodah Kandala PhD

$0.00

Subscribers read for free.

Read for Free

$75.00$ 75 00 to buyKindle Edition

Get it TODAY, Jan 29

5 out of 5 stars 1

Sold by: Amazon Digital Services LLC

Cancer Biology and Genomics for Disease Diagnosis (Series C: e-Books on Cancer & Oncology Book 1)

Aug 10, 2015 | Kindle eBook

by Larry H Bernstein MD FCAP and Prabodh Kumar Kandala PhD

$0.00

Subscribers read for free.

Read for Free

$75.00$ 75 00 to buyKindle Edition

Get it TODAY, Jan 29

Sold by: Amazon Digital Services LLC

Genomics Orientations for Personalized Medicine (Frontiers in Genomics Research Book 1)

Nov 22, 2015 | Kindle eBook

by Sudipta Saha PhD and Ritu Saxena PhD

$0.00

Subscribers read for free.

Read for Free

$75.00$ 75 00 to buyKindle Edition

Get it TODAY, Jan 29

Sold by: Amazon Digital Services LLC

Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics (Series E: Patient-Centered Medicine Book 3)

Dec 26, 2015 | Kindle eBook

by Larry H. Bernstein MD FACP and Aviva Lev-Ari PhD RN

$0.00

Subscribers read for free.

Read for Free

$75.00$ 75 00 to buyKindle Edition

Get it TODAY, Jan 29

Sold by: Amazon Digital Services LLC

Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases

Dec 26, 2015 | Kindle eBook

by Justin D. Pearlman MD ME PhD MA FACC and Ritu Saxena PhD

$0.00

Subscribers read for free.

Read for Free

$75.00$ 75 00 to buyKindle Edition

Get it TODAY, Jan 29

Sold by: Amazon Digital Services LLC

5        Style Setting: Instruction manuals for Journal, Articles, Books

As BioMed e-Series Editor–in-Chief, Aviva Lev-Ari, PhD, RN was responsible for

·       All the documentation (Instruction manuals) on Style setting, and for

·       Training all team members

·       Journal Articles Format

·       Journal Comment Exchange Format

·       e-Books Production Process:

1.               Volume creation from Journal’s Article Archive,

2.               Format Translation from HTML to .mobi for Kindle devices,

3.               Proof reading process,

4.               Title release,

5.               Book electronic Upload to Amazon.com Cloud.

6.               Connection of all articles and e-Books to Social Media, Ping back generation by mentioning other related articles published in the Journal

 

Lastly, 6, below

6        Annual Workflow Management of Multiple eTOCs – Multi-year Book Publishing Scheduling Plan, 2013 – Present

 

Title Date of Publication Number of Pages
Perspectives on Nitric Oxide in Disease Mechanisms 6/21/2013 895
Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation 11/30/2015 11039 KB
Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics 11/29/2015 12333 KB
Regenerative and Translational Medicine: The Therapeutics Promise for Cardiovascular Diseases 12/26/2015 11668 KB
Genomics Orientations for Personalized Medicine 11/23/2015 11724 KB
Cancer Biology & Genomics for Disease Diagnosis 8/11/2015 13744 KB
Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery 5/18/2017 5408 pages
Metabolic Genomics and Pharmaceutics 7/21/2015 13927 KB
The Immune System, Stress    Signaling, Infectious Diseases and Therapeutic Implications 9/4/2017 3747 pages
The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures 10/16/2017 826 pages
Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders 12/9/2017 2862 pages
Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics 12/27/2015 11125 KB
Medical 3D BioPrinting – The Revolution in Medicine, Technologies for Patient-centered Medicine: From R&D in Biologics to New Medical Devices 12/30/2017 1005 pages
Pharmacological Agents in Treatment of Cardiovascular Disease

 

 Work-in-Progress, Expected Publishing date in 2018 ???
Interventional Cardiology and Cardiac Surgery for Disease Diagnosis and Guidance of Treatment Work-in-Progress, Expected Publishing date in 2018

 

 ???

 

Read Full Post »

2018 MassBio Annual Meeting March 21, 2017 8:00 AM – March 22, 2017 4:00 PM, Royal Sonesta Boston, Cambridge MA

Posted in Conference Coverage with Social Media on February 6, 2018| Leave a Comment »

2018 MassBio Annual Meeting March 21, 2017 8:00 AM – March 22, 2017 4:00 PM, Royal Sonesta Boston, Cambridge MA

 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group represented by Founder & Director, Aviva Lev-Ari, PhD, RN will cover this event in REAL TIME using Social Media

@pharma_BI

@AVIVA1950

Due to Snow Storm Warning I did not attend

 

Register

Register

Member Rates

$675.00 Biotechnology
$350.00 Academic, Hospitals, & Non-Profit
$675.00 Associates
$350.00 Government

Non-Member Rates

$875.00 Non-Member
$500.00 Non-Profit
$500.00 Government
$250.00 Student

MASSBIO ANNUAL MEETING
Wednesday, March 21 & Thursday, March 22, 2018
Royal Sonesta, Cambridge

2018 MassBio Annual Meeting

– 
Royal Sonesta Boston40 Edwin Land BoulevardCambridge MA US 02142

Venue WebsiteGet Directions

SPEAKERS

  • Andrew Adams, President, Publicis Health Solutions
  • Derek Adams,PhD, Chief Technology & Manufacturing Officer, bluebird bio
  • Dolores Baksh, PhD, Innovation Leader, Cell Therapy Technologies, GE Healthcare
  • Ashvin Bashyam, PhD candidate in the Department of Electrical Engineering & Computer Science, MIT, Co-President, MIT Biotechnology Group
  • Angela Belcher, PhD, James Mason Crafts Professor, Professor of Biological Engineering, Materials Science and Engineering, Koch Institute for Integrative Cancer Research, MIT
  • Maria Berkman, MD, Director, Broadview Ventures
  • Aaron Bernstein, PhD Candidate in Cellular & Molecular Physiology, Tufts University, President, Tufts Biomedical Business Club
  • Kerrie Brady, Chief Business Officer, Centrexion
  • Marta Bralic, Vice President of Business Development, Flatiron Health
  • Caeleigh Brown
  • Jim Burns, PhD, President & CEO, Casebia Therapeutics
  • Abbie Celniker, PhD, Partner, Third Rock Ventures
  • Anna Christo, Senior Director, Science and Technology, Alexandria Real Estate Equities, Inc.
  • George Church, PhD, Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology
  • Bob Coughlin, President & CEO, MassBio
  • Agnieszka Czechowicz, MD, PhD, Assistant Professor of Pediatrics (Stem Cell Transplantation), Stanford University
  • Matt Dallas, Chief Financial Officer, AVEO Pharmaceuticals
  • Frank David, MD, PhD, Founder and Managing Director, Pharmagellan
  • Mitch DeKoven, Principal, – Health Economics and Outcomes Research, Real World Insights, IQVIA
  • Oliver Dodd, Co-Founder, Remora Therapeutics
  • Alin Dragos, Digital Currency Initiative Product Management, MIT Media Lab
  • Nick Eliovits, Managing Partner, Olive Tree Capital
  • Jeff Elton, Managing Director and Global Head, Predictive Health Intelligence, Accenture
  • Giovanna Fessenden, Of Counsel, Hamilton Brook Smith Reynolds
  • Naomi Fried, PhD, Founder and CEO, Health Innovation Strategies
  • Stephen Galebach, Galebach Law
  • Brian Gallagher, Partner, SR One
  • Brett Geiger, PhD candidate in the Department of Biological Engineering, MIT, Co-Presidents, MIT Biotech Group
  • Rebecca Gibbs, PhD candidate in Biological and Biomedical Sciences, Harvard University, President, Harvard Biotech Club
  • Michael Gibson, MD, CEO, Baim Institute for Clinical Research
  • David Glass, PhD, D. Glass Associates
  • Laurie Glimcher, MD, President and CEO, Dana-Farber Cancer Institute
  • Marc Goldberg, Managing Director, BioVentures Investors
  • Arjun Goyal, MD, Co-founder and Managing Director, Vida Ventures
  • Aine Hanly, Vice President, Process Development and Massachusetts Site Head, Amgen
  • Peter Hecht, PhD, CEO, Ironwood Pharmaceuticals
  • Martin Heidecker, PhD, Director, Investment Manager, Boehringer Ingelheim Venture Fund
  • Peter Hein, MD, PhD, External Innovation Lead and Director, Innovative Medicines Unit, Grünenthal
  • Arthur Hiller, CEO, Antyllus Therapeutics, Inc., and Principal, Hiller Life Sciences Strategies, LLC
  • Lori Hu, Principal, Vertex Ventures
  • Laura Indolfi, PhD, CEO & Co-Founder, PanTher Therapeutics
  • Matt Kapusta, CEO, uniQure
  • Stephen Kennedy Smith, Principal Park Agency – Kennedy Enterprises
  • Ash Khanna, PhD, Venture Partner, Pivotal bioVenture Partners
  • Daniel Kohane, MD PhD, Boston Children’s Hospital
  • Julie Krop, MD, Chief Medical Officer and Senior Vice President of Clinical Development and Regulatory Affairs, AMAG Pharmaceuticals
  • Robert Langer, ScD, the David H. Koch Institute Professor, MIT
  • Harvey Lodish, PhD, Professor of Biology and Biological Engineering, MIT and Founding Member, Whitehead Institute
  • David Lucchino, Co-Founder, President & CEO, Frequency Therapeutics
  • Larry Lucchino, Boston Red Sox President/CEO Emeritus and Chairman of the Board, Jimmy Fund
  • Anna Maiques, CEO, Neuroelectrics
  • Eddie Martucci, CEO, Akili
  • Frank McGillin, Chief Commercial Officer, NeuroMetrix
  • Terry McGuire, Founding Partner, Polaris Partners
  • Marian McKee, PhD, Senior Director and Head of Global Operational Development Services, MilliporeSigma
  • Lindsay McNair, MD, Chief Medical Officer, WIRB-Copernicus Group
  • Anne Mostue, Anchor, Reporter, Bloomberg News
  • Christopher Murphy, Chief Manufacturing Officer, Brammer Bio
  • Marian Nakada, PhD, Vice President, Venture Investments, Johnson & Johnson Innovation
  • Dana Ono, PhD, Managing Partner, OLS Ventures
  • Lucinda Orsini, Associate Chief Science Officer, International Society For Pharmacoeconomics and Outcomes Research
  • Michio Painter, PhD, Co-Founder and CEO, Blue Therapeutics
  • Maria Palasis, PhD, President & CEO, 480 Biomedical
  • Catherine Parham, Vice President, Clinical Therapeutic Area Head, Shire
  • Leila Pirhaji, PhD, CEO, ReviveMed Technologies
  • Chandra Ramanathan, PhD, Head, East Coast Innovation Center, Bayer
  • Jim Roach, MD, Chief Medical Officer, Pulmatrix
  • Marc Rubenstein, Partner, Ropes & Gray
  • Stephen Sallan, MD, Quick Family Chair, Pediatric Oncology, Dana Farber Cancer Institute
  • Rev. Dr. James Sherblom
  • Al Sokol, Partner, McDermott, Will & Emery
  • Lesley Solomon, Senior Vice President Innovation, Chief Innovation Officer, Dana-Farber Cancer Institute
  • Christopher de Souza, PhD, Director, Broadview Ventures
  • Edie Stringfellow, Director of Diversity & Inclusion, MassBio
  • John Tagliamonte, Chief Operation Officer, WntRx and EIR, MassBio Science
  • Barry Ticho MD PhD, Chief Medical Officer, Stoke Therapeutics
  • Praveen Tipirneni, MD, President & CEO, Morphic Therapeutic
  • Ailis Tweed-Kent, MD, CEO, Cocoon Biotech & Attending Physician, Massachusetts General Hospital
  • Stephen Ubl, President & CEO, PhRMA
  • Akshay Vaishnaw, MD, PhD, Executive Vice President of R&D and Chief Medical Officer, Alnylam Pharmaceuticals
  • Francois Valencony, General Manager, Mérieux Développement
  • Ramani Varansai, President & CEO, X-Biotix Therapeutics, Inc.
  • Terry Vance, Chief Business Officer, BioMotiv
  • Alex Waldron, Chief Commercial Officer, Pear Therapeutics
  • Russ Wilcox, Partner, Pillar
  • Susan Windham-Bannister, PhD, President & CEO, Biomedical Growth Strategies
  • Cissy Young, PhD, Managing Director, Russell Reynolds Associates

https://www.massbio.org/events/2018-massbio-annual-meeting-2487?tab=speakers

Day 1

Welcome

Plenary
8:30 am – 9:00 am

Keynote Address

Plenary
9:00 am – 9:30 am

Jimmy Fund & Dana Farber Cancer Institute: 70 Years of Helping Patients

Plenary
9:30 am – 10:15 am

Networking Break

10:15 am – 10:30 am

Diversity in Leadership

Business
10:30 am – 11:15 am

The Changing Role of Chief Medical Officers

Science
10:30 am – 11:15

Getting to Better Pain Relief

Emerging Priorities
10:30 am – 11:15 pm

A Candid Conversation with Steve Ubl of PhRMA and Bob Coughlin of MassBio

Plenary
11:15 am – 12:00 pm

Lunch

12:00 pm – 12:15 pm

Presentation of the 2018 Innovative Leadership Award to Jeffrey Leiden, MD PhD, Chairman, President & CEO, Vertex Pharmaceuticals

Plenary
12:15 pm – 12:45pm

Fireside Chat: Life Lessons in the Life Sciences

Plenary
12:45 pm – 1:30 pm

Rock Stars of Life Sciences

Plenary
1:30 pm – 2:30 pm

Networking Break

2:30 pm – 3:00 pm

Tenacity, Perseverance, Pivots, and Courage in Biotech

Business
3:00 pm – 3:45 pm

Addressing the Complexities in Gene Therapy and Regenerative Technologies

Science
3:00 pm – 3:45 pm

Bitcoin, ICOs and Blockchain in Life Sciences: Hype or Hope?

Emerging Priorities
3:00 pm – 3:45 pm

The Nature of Real Data in Health Economics

Business
3:45 pm – 4:30 pm

Tackling the Intractable: Future of Cardiovascular Diseases

Science
3:45 pm – 4:30 pm

Physicians and Clinicians Speak About Drugs

Emerging Priorities
3:45 pm – 4:30 pm

World Series Reception featuring the 2007 & 2012 Trophies and an Appearance from Wally the Green Monster

4:30 pm – 6:00 pm

Day 2

Breakfast

8:30 am – 9:00 am

MassBio Founders Discuss the Industry: 1985 to Today

Plenary
9:00 am – 9:45 am

Venture Capitalist Speak About the Future of Deal Making

Business
9:45 am – 10:45 am

Digital Therapeutics

Science
9:45 am – 10:45 am

MassCONNECT: What I Learned

Emerging Priorities
9:45 am – 10:45 am

Networking Break

10:45 am – 11:15 am

BioPharma Investor Funds: How Are They Different?

Business
11:15 am – 12:00 pm

University Biotech Clubs: Their Mission and Vital Role in the Ecosystem

Science
11:15 am – 12:00 pm

Family Office

Emerging Priorities
11:15 am – 12:00 pm

Lunch

12:00 pm – 12:20 pm

Mayor Martin J. Walsh, City of Boston

Plenary
12:30 pm – 12:35 pm

Innovative School of the Year Award to Essex Technical High School

Plenary
12:35 pm – 1:00 pm

Keynote Address

Plenary
12:45 pm – 1:30 pm

Networking Dessert Reception

1:30 pm – 2:00 pm

 ABOUT

MassBio’s largest event, drawing over 400 industry leaders, the Annual Meeting is a two-day event that focuses on the most timely and critical challenges facing the Massachusetts biopharma industry.

From breakthroughs in scientific endeavors to startups and new business ventures, the Annual Meeting will cover the most innovative advancements in the industry, presented in new and interactive formats. It will recognize and award industry leaders, provide ample networking opportunities, and showcase Massachusetts as the leader in the biopharma industry worldwide.

This year, we’ll have conference-wide sessions, keynotes and three breakout tracks: Business, Science and Emerging Priorities.

Highlights include:

  • Fireside chat with Robert Langer and Terry McGuire: Life Lessons in the Life Sciences.

Topics to be discussed include:

  • Diversity in Leadership
  • Health Economics
  • Venture Capital: traditional, corporate and family offices
  • Tenacity in Biotechnology
  • Regenerative Technologies
  • Opioids
  • Digital Currency
  • Physicians and Clinicians
  • and more.

 

For sponsorship opportunities, contact Elizabeth Steele.

 Signature Events,

SOURCE

https://www.massbio.org/events/2018-massbio-annual-meeting-2487

Read Full Post »

12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media on January 18, 2018| Leave a Comment »

12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge

Reporter: Aviva Lev-Ari, PhD, RN

http://usaindiachamber.org/speaker.php

@USAIC

#USAIC2018

 

Announcement

Aviva Lev-Ari, PhD, RN,

Founder and Director of LPBI Group will be in attendance covering the event in REAL TIME

@pharma_BI

@AVIVA1950

 

All TWEETS from LPBI’s Twitter.com handles at

@USAIC

#USAIC2018

by

@pharma_BI

@AVIVA1950

BioPharma & Healthcare Summit – May 8, 2018

Chair and Emcee – Dr. Andrew Plump, Chief Medical & Scientific Officer, Takeda Pharmaceuticals

Time Topic
8-45 AM – 9-10 AM Registration and Networking
9-10 AM – 9-25 AM Welcome address: Karun Rishi, President, USA-India Chamber of Commerce (USAIC)

Opening comments: Dr Andrew Plump, Chief Medical & Scientific Officer, Takeda Pharmaceuticals
9-25 AM – 10-15 AM Panel Discussion: Industry-Academic Research Partnerships

Panelists:

  • Dr. Chas Bountra, Chief Scientist, Structural Genomics Consortium Oxford, University of Oxford
  • Dr. Jim Glasheen, Executive Vice Chancellor, University of Massachusetts Medical School
  • Dr. Jonathan Epstein, Executive Vice Dean & Chief Scientific Officer, Perelman School of Medicine, University of Pennsylvania
  • Dr. Nirmal Kumar Ganguly, President, Apollo Hospitals Educational & Research Foundation
  • Dr. Sridaran Natesan, Head – Strategic Initiatives & Scientific Relations, R&D, Sanofi North America

Moderator:
Juan Harrison, Vice President, Head of Strategic Academic Alliances, Takeda Pharmaceuticals
10-15 AM – 11-05 AM Panel Discussion: Neuro Diseases                                                                                                          

Panelists:

  • Dr. Alfred Sandrock, Executive Vice President & Chief Medical Officer, Biogen
  • Dr. David Goldstein, Director, Institute for Genomic Medicine, Columbia University Medical Center
  • Dr. Maurizio Fava, Associate Dean, Clinical & Translational Research, Harvard Medical School
  • Dr. Meeta Chatterjee, Head, Business Strategy & Operations, Business Development & Licensing, Merck Research Labs
  • Dr. Steven Paul, President and Chief Executive Officer, Voyager Therapeutics

Moderator:
Dr. Steve Uden, Co-Founder, Rallybio
11-05 AM -11-35 AM Networking Break
11-35 AM – 12-25 PM Panel Discussion: Oncology

Panelists:

  • Dr. Bruce Chabner, Director of Clinical Research, Mass General Hospital Cancer Center/Harvard Medical School
  • Dr. Kurt Stoeckli, President and Chief Scientific Officer, Glenmark Pharmaceuticals
  • Dr. Philip Rowlands, Head of the Oncology Therapeutic Area Unit, Takeda Pharmaceuticals
  • Dr. Victoria Richon, President & CEO, Ribon Therapeutics
  • Dr. Rakesh Jain, Director, E.L. Steele Laboratory of Tumor Biology,  Mass General Hospital Cancer Center/HMS

Moderator:
Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School
12-25 PM – 1-00 PM Fireside Chat:

  • Dr. Ansbert Gadicke, Founder & Managing Director, MPM Capital
  • Dr. Stelios Papadopoulos, Chairman, Biogen
  • Dr. Tsutomu Une, Senior Corporate Advisor, GCA Corporation

Moderator: 
Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School
1-00 PM – 2-40 PM Luncheon Panel Discussion: Technology Platforms

Panelists:

  • Chris Benko, Co-Founder & CEO, Koneksa Health
  • Colin Hill, Chairman & CEO, GNS Healthcare
  • Dr. Peter Mueller, Chairman, BioXcel Therapeutics
  • Dr. Shahram Ebadollahi, Vice President, Innovations & Chief Scientific Officer, IBM Watson Health Group, IBM
  • Dr. Vijay Chandru, Chairman, Strand Life Sciences

Moderator:
Dr. Ajay Dhankhar, Senior Partner, McKinsey and Company
2-40 PM – 3-15 PM Networking & Tea Break
3-15 PM – 3-35 PM BioPharma: An Extraordinary Disruption

Dr. Ajay Dhankhar, Senior Partner, McKinsey and Company
Sastry Chilukuri, Partner, McKinsey and Company
3-35 PM – 4-30 PM Panel Discussion: Drug Discovery and Development

Panelists:

  • Dr. Andrew Plump, Chief Medical & Scientific Officer, Takeda Pharmaceuticals
  • Dr. Mathai Mammen, Global Head of R&D, Janssen Pharmaceutical- Johnson & Johnson
  • Dr. Michael Ehlers, Executive Vice President and Head of Research & Development, Biogen

Moderator:
Dr. Martin Mackay, Co-Founder and CEO, Rallybio
4-30 PM – 5-05 PM Fireside Chat:

  • Dr. George Daley, Dean, Harvard Medical School
  • Dr. Susan Hockfield, President Emerita & Professor of Neuroscience, Massachusetts Institute of Technology (MIT)

Moderator:
Dr Andrew Plump, Chief Medical and Scientific Officer, Takeda Pharmaceuticals
5-05 PM – 5-10 PM Closing Remarks
5-10 PM – 6-30 PM Cocktails & Networking Reception

*Luncheon Panel Discussion: Lunch will be served at the table at 12:50 PM. Panel will start at 1:40 PM

* Speaker and Timings subject to change

Some of the Speakers and Participants

Dr. Andrew Plump
Chief Medical & Scientific Officer
Takeda Pharmaceuticals
Dr. James Bradner
President
Novartis Institutes for BioMedical Research
Prof. Susan Hockfield
President Emerita
MIT
Dr. Mathai Mammen
Global Head of R&D
Janssen R&D
Dr. Stelios Papadopoulos
Chairman- Biogen
Chairman- Exelixis

Dr. Martin Mackay
Co-Founder
Rallybio
Dr. R.K. Vats*
Additional Secretary
Ministry of Health & Family Welfare
Dr. George Daley
Dean
Harvard Medical School
Sanat Chattopadhyay
President- Merck Manufacturing Division
Merck & Co.
Dr. Steven Paul
President & CEO
Voyager Therapeutics

Dr. Bruce Chabner
Director of Clinical Research
Mass General Hospital Cancer Center
Dr. Eswara Reddy*
Drugs Controller General of India
Ministry of Health & Family Welfare
Dr. William W. Chin
Professor of Medicine, Emeritus
Harvard Medical School
Dr. Alfred Sandrock
Executive Vice President & CMO
Biogen
Dr. Jonathan Epstein
Executive Vice Dean & CSO
Perelman School of Medicine, UPenn

Dr. Chas Bountra
Chief Scientist
Structural Genomics Consortium Oxford
Dr. Katherine Bowdish
Head
Sanofi Sunrise
Dr. Philip Rowlands
Head of the Oncology TAU
Takeda Pharmaceuticals
Dr. Sridaran Natesan 
Vice President- Strategic Initiatives
Sanofi
Jim Gilbert
Senior Partner
Flagship Pioneering

Dr. Jim Glasheen
Executive Vice Chancellor
UMass Medical School
Dr. Steve Hitchcock
Global Head of Research
Takeda Pharmaceuticals
Dr. Victoria Richon
President & CEO
Ribon Therapeutics
Dr. Michael Ehlers
Executive Vice President R&D
Biogen
Prof. Nirmal Kumar Ganguly
Former Director General
ICMR

Dr. Rakesh Jain
Prof. of Tumor Biology
MGH/Harvard Medical School
Dr. Daniel Jay
Dean- Sackler School
Tufts University
Dr. Michael Mendelsohn
Founder & Executive Chairman
Cardurion Pharmaceuticals
Dr. Christiana Bardon
Managing Director
MPM Capital
Dr. Tsutomu Une
Senior Corporate Advisor
GCA Corporation

Dr. Maurizio Fava
Associate Dean for Translational Research
Harvard Medical School
Dr. Peter Mueller
Chairman
BioXcel Therapeutics
Dr. Anthony Muslin
Head of Cardiovascular & Fibrosis Research
Sanofi
Brad Margus
Chief Executive Officer
Cerevance
Dr. Steve Uden
Co-Founder
Rallybio

Dr. Kurt Stoeckli
President & CSO
Glenmark Pharmaceuticals
Dr. Shahram Ebadollahi
Chief Science Officer
IBM Watson Health Group
Dr. Carl Goldfischer
Managing Director
Bay City Capital
Philippe Lopes-Fernandes 
Senior Vice-President
Merck KGaA, Darmstadt, Germany
Dr. Michael Cima
Associate Dean of Innovation
MIT School of Engineering

Benjamin Thorner
Head of Business Dev & Licensing
Merck Research Labs
Dr. Tal Zaks
Chief Medical Officer
Moderna Therapeutics
Dr. Mario Saltarelli
SVP- Early Dev & Neurology
Vertex Pharmaceuticals
Dr. Ole Isacson
Professor of Neurology
Harvard Medical School
Dr. Iman El-Hariry
Chief Medical Officer
ERYTECH

Dr. Raju Kucherlapati
Professor of Genetics
Harvard Medical School
Dr. Kimberly Wagner
President & COO
CiBO Technologies
Dr. Lex H.T. Van der Ploeg
Chief Scientific Officer
Rhythm Pharma
Dr. Christopher Wright
Chief Development Officer
Ironwood Pharmaceuticals
Dr. Iya Khalil
Co-Founder & Exe. Vice President
GNS Healthcare

Juan Harrison
VP, Head of Strategic Academic Alliances
Takeda Pharmaceuticals
Dr. Vijay Chandru
Chairman
Strand Life Sciences
Vikas Sinha
Managing Director
MPM Capital
Dr. David Goldstein
Director-Institute for Genomic Medicine
Columbia University Medical Center
Dr. Birgit Schoeberl
Global Head Modeling & Simulation
Novartis Institutes for BioMed Res.

Dr. Ajay Dhankhar
Senior Partner
McKinsey and Company
Dr. Markus Haeberlein
Head of Discovery
Alkermes
Dr. Ajay Nirula
Vice President-Immunology
Eli Lilly
Dr. Isabel Aznarez
Co-Founder & Head of Biology
Stoke Therapeutics
Dr. Harith Rajagopalan
Co-Founder & CEO
Fractyl

Dr. Christopher Locher
Co-Founder & CEO
Versatope Therapeutics
Colin Hill
Co- Founder & Chairman
GNS Healthcare
Dr. Thomas Schuetz
Co-founder & CEO
Compass Therapeutics
Constantine Chinoporos
Chief Business Officer
Boston Pharmaceuticals
Dr. Frank Bobe
Entrepreneur-in-Residence
Wyss Institute

Sanjiv Patel
President & CEO
Relay Therapeutics
Dr. Rhonda Kaufman
Director
Foresite Capital Management
Dr. Meeta Chatterjee
Head- Business Strategy, BD&L
Merck Research Laboratories
Vinay Ranade
Head of Biosimilars
Reliance Life Sciences
Dr. Robert Copeland
Co Founder & President
Accent Therapeutics

Winston Kung
Chief Operating Officer
PMV Pharma
Dr. Femida Gwadry-Sridhar
Founder & CEO
Pulse Infoframe
Dr. Barry Ticho
Chief Medical Officer
Stoke Therapeutics
Dr. Patrick Anquetil
Chief Executive Officer
Portal Instruments
John Ripple
Chief Executive Officer
Exonics Therapeutics

Dr. James Cassella
Chief Development Officer
Concert Pharmaceuticals
Chris Benko
Co-Founder & CEO
Koneksa Health
Dr. Stefan Scherer
Head Early Dev, Strategy & Innovation
Novartis
Dr. Michael Vasconcelles
Chief Medical Officer
Unum Therapeutics
Jeff Hackman
Chief Operating Officer
Novelion Therapeutics

Read Full Post »

2018 Annual World Medical Innovation Forum Artificial Intelligence April 23–25, 2018 Boston, Massachusetts  |  Westin Copley Place

Posted in Artificial Intelligence Applications in Health Care, Conference Coverage with Social Media, Scientific & Biotech Conferences: Press Coverage on January 18, 2018| Leave a Comment »

2018 Annual World Medical Innovation Forum Artificial Intelligence April 23–25, 2018 Boston, Massachusetts  | Westin Copley Place

https://worldmedicalinnovation.org/

https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg

3.1.5

3.1.5   2018 Annual World Medical Innovation Forum Artificial Intelligence April 23–25, 2018 Boston, Massachusetts  | Westin Copley Place https://worldmedicalinnovation.org/, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

Announcement

Aviva Lev-Ari, PhD, RN,

Founder and Director of LPBI Group will be in attendance covering the event in REAL TIME

@pharma_BI

@AVIVA1950

On 5/2015

4/2018

All TWEETS from LPBI’s Twitter.com handles at

#WMIF18

@pharma_BI

@AVIVA1950

Monday, April 23, 2018

7:00 am – 8:00 am
GE Foyer
Breakfast
7:00 am – 8:00 am
Nuance Foyer
Registration
8:00 am – 11:30 am
NVIDIA Ballroom
First Look: The Next Wave of AI Breakthroughs in Health Care

Early career Harvard Medical School investigators kick-off the 2018 World Medical Innovation Forum with rapid fire presentations of their high potential new technologies. Nineteen rising stars from Brigham Health and Massachusetts General Hospital will give ten-minute presentations highlighting their discoveries and insights that will disrupt the field of artificial intelligence. This session is designed for investors, leaders, donors, entrepreneurs and investigators and others who share a passion for identifying emerging high-impact technologies. To view speakers and topics, click here.

Moderator: Trung Do
  • VP, Business Development, Innovation, PHS
Moderator: Clare Tempany, MD
  • Vice Chair of Research at the Department of Radiology, BWH; Ferenc Jolesz MD Professor of Radiology, HMS
11:30 am – 11:45 am
Break and Move to Discovery Café Workshops
11:45 am – 1:00 pm
3rd Floor and 7th Floor
Discovery Café Workshops

Lunch with Top Leadership from across Partners HealthCare and Industry.

Seven intensive workshops addressing cutting-edge artificial intelligence topics. To view topics and speakers, click here

1:00 pm – 1:20 pm
Break
1:20 pm – 1:45 pm
NVIDIA Ballroom
Opening Remarks
The Honorable Charlie Baker
  • Governor of the Commonwealth of Massachusetts
Anne Klibanski, MD
  • Chief Academic Officer, PHS; Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, HMS; 2018 Forum Co-Chair
David Torchiana, MD
  • CEO, PHS
1:45 pm – 2:25 pm
NVIDIA Ballroom
Reflecting on the Impact of AI at the Bed and the Bench: Chairs Roundtable

Senior clinical leaders, current and past Forum Chairs, will share perspectives on the range of impact of AI on clinical practice. Discussion will highlight the rapid evolution of AI as a practical clinical tool and short and mid-term prospects for adoption in cancer, cardiovascular and neurological care.

Moderator: Sue Siegel
  • CIO and CEO, Business Innovations, GE
Keith Dreyer, DO, PhD
  • Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS
Anne Klibanski, MD
  • Chief Academic Officer, PHS; Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, HMS; 2018 Forum Co-Chair
Calum MacRae, MD, PhD
  • Vice Chair for Scientific Innovation, Department of Medicine, BWH; Chief Executive, One Brave Idea, BWH; Associate Professor of Medicine, HMS; 2017 Forum Co-Chair
Gregg Meyer, MD
  • Chief Clinical Officer, PHS; Professor of Medicine, HMS; 2018 Forum Co-Chair
Anthony Rosenzweig, MD
  • Chief, Cardiology Division, MGH; Professor of Medicine, HMS; 2017 Forum Co-Chair
2:25 pm – 3:15 pm
NVIDIA Ballroom
Can AI Based Drug Development Feed A Hungry Pipeline?

Given the scarcity of late-stage assets, prolonged timelines and enormous costs of bringing drugs to market, AI-based approaches to target discovery, drug design and drug repurposing hold significant promise to positively disrupt the existing R&D paradigm.

Moderator: Anthony Philippakis, MD, PhD
  • Chief Data Officer, Broad Institute; Cardiologist, BWH; Venture Partner, Google Ventures
Andrew Hopkins
  • CEO, Exscientia
Sekar Kathiresan, MD
  • Director, Center for Genomic Medicine, MGH; Ofer and Shelly Nemirovsky MGH Research Scholar; Associate Professor of Medicine, HMS
Thomas Lynch, MD
  • EVP and CSO, R&D, Bristol-Myers Squibb
Niven Narain
  • CEO, BERG
Mike Nohaile, PhD
  • SVP, Strategy, Commercialization & Innovation, Amgen
3:15 pm – 4:05 pm
NVIDIA Ballroom
Smart EHRs: AI for All

The first wave of EHR adoption has focused primarily on digitizing the patient record – with a more recent focus on building interactive clinical decision support capabilities. Development and implementation of CDS applications currently  requires  clinical staff to observe trends in data, develop protocols to act on these trends and work with technical staff to codify the logic into executable form. As NLP and computer vision capabilities become more advanced, algorithms will identify and propose actions reflecting patterns in the data. The panel will discuss existing challenges and whether AI technology will ultimately support an unsupervised learning approach in the EHR to identify trends and possible responses at both the patient and population level?

Moderator: O’Neil Britton, MD
  • SVP and CMO, MGH
Dan Burton
  • CEO, Health Catalyst
Seth Hain
  • Director, Analytics & Machine Learning, Epic
Sudhir Kulkarni
  • President, Digital, Persistent Systems
Noga Leviner
  • CEO, Picnic Health
Diana Nole
  • CEO, Wolters Kluwer Health
4:05 pm – 4:55 pm
NVIDIA Ballroom
AI and the Cost of Trials: The Impact of Real World and Real Time Evidence

AI based approaches to conduct faster and more efficient clinical trials are beginning to emerge. Current approaches include applying predictive tools to perform more targeted patient recruitment and more accurate eligibility assessment. Panelists will discuss timelines for AI technology to have a measurable effect on trial cost and time to conduct the trial. Bottlenecks to applying this technology at scale and whether there will be a measurable effect on the cost of bringing drugs to market over the next decade will also be examined.

Moderator: Krishna Yeshwant, MD
  • Partner, Google Ventures; Instructor in Medicine, BWH
Amy Abernethy, MD, PhD
  • CMO, CSO & SVP Oncology, Flatiron Health
Ramesh Durvasula, PhD
  • VP, Research IT, Eli Lilly and Company
Colin Hill
  • CEO, GNS Healthcare
Jackie Hunter, PhD
  • CEO, BenevolentAI
Joseph Scheeren, PharmD
  • Senior Advisor, R&D, Bayer
Stephen Wiviott, MD
  • Executive Director, Clinical Trials Office, PHS; Associate Professor of Medicine, HMS
5:00 pm – 6:00 pm
Nuance Foyer
Opening Reception

Tuesday, April 24, 2018

7:15 am – 7:50 am
Nuance Foyer
Continental Breakfast
7:50 am – 8:00 am
NVIDIA Ballroom
Opening Remarks
Chris Coburn
  • Chief Innovation Officer, PHS; President, Partners HealthCare International, PHS
8:00 am – 8:50 am
NVIDIA Ballroom
Will AI Bend the Cost and Access Curve

Historical barriers have driven increased medical costs and decreasing access since the 1960s. The “Iron Triangle of Healthcare” continues to represent a tenuous balance of quality, cost and accessibility – economists have lamented attempts to optimize one characteristic at the expense of the others. The accumulation of innovations in care delivery (e.g. shift to lower cost providers and settings), population management, value based reimbursement and hospital administration are having a measurable effect. Can AI based technologies accelerate the pace of innovation and finally bend the cost and access curves in the US?

Moderator: Timothy Ferris, MD
  • CEO, MGPO
Roy Beveridge, MD
  • SVP and CMO, Humana
Leonard D’Avolio, PhD
  • CEO, Cyft, Inc.
Peter Orszag, PhD
  • Vice Chairman, Investment Banking and Managing Director, Lazard Freres
8:50 am – 9:40 am
NVIDIA Ballroom
Drug Therapy Redefined Through Machine Learning

The drug development process is highly complex and has many drivers. The panel will discuss the strategic impact of AI on the entire process and the implications for healthcare overall. How will the combination of factors – research strategy, drug development, regulatory approvals, reimbursement and clinical effectiveness – be influenced by the implementation of AI. Panelists will discuss short and mid-term prospects and whether AI will ultimately lead to a restructuring of the pharma model to develop new therapies.

Moderator: Jean-François Formela, MD
  • Partner, Atlas Venture
Jay Bradner, MD
  • President, Novartis Institutes for Biomedical Research
Mark Murcko, PhD
  • CSO, Relay Therapeutics
Georgia Papathomas, PhD
  • SVP, Global Head of Data Sciences, Johnson & Johnson
Eric Perakslis, PhD
  • CSO, Datavant
Gregg Talbert, PhD
  • Global Head of Digital and Personalized Health Care Partnering, Roche
9:40 am – 10:10 am
NVIDIA Ballroom
1:1 Fireside Chat: Atul Gawande, MD
Introduction by: John Fish
  • CEO, Suffolk; Chairman of Board Trustees, Brigham Health
Moderator: Elizabeth Nabel, MD
  • President, Brigham Health; Professor of Medicine, HMS
Atul Gawande, MD
  • Executive Director, Ariadne Labs; Samuel O. Thier Professor of Surgery, HMS; Surgeon, BWH
10:10 am – 10:25 am
Nuance Foyer
Morning Break
10:25 am – 11:15 am
NVIDIA Ballroom
Data Engineering in Healthcare: Liberating Value

The promise of machine learning and big data in in healthcare seems boundless – but healthcare data is massive and complex, and organizing and managing this data is the first step to an AI-empowered healthcare system.  Technology giants are investing in solutions to overcome these data engineering challenges, but with many visions of the future of healthcare data jockeying for dominance, what will the future of healthcare data really look like?  Can we finally liberate the value of data for patient care? And how will it happen?

Moderator: Mark Michalski, MD
  • Executive Director, MGH & BWH CCDS
Iain Buchan, MD
  • ‎Director of Healthcare Research, Microsoft Research
Patricia Florissi
  • VP and Global CTO, Sales, Dell EMC
James Mault, MD
  • SVP and CMO, Qualcomm Life
Greg Moore, MD, PhD
  • VP, Healthcare, Google Cloud
Shawn Murphy, MD, PhD
  • Chief Research Information Officer, PHS; Associate Professor of Neurology, HMS
Timothy Tuttle, PhD
  • CTO, Cognitive Collaboration Group, Cisco
11:15 am – 11:45 am
NVIDIA Ballroom
1:1 Fireside Chat: Jensen Huang, CEO, NVIDIA
Introduction by: Scott Sperling
  • Co-President, Thomas H Lee Partners; Chairman of the Board of Directors, PHS
Moderator: Keith Dreyer, DO, PhD
  • Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS
Jensen Huang
  • CEO, NVIDIA
12:00 pm – 1:00 pm
GE Ballroom
Lunch
12:30 pm – 1:00 pm
GE Ballroom
1:1 Fireside Chat: Paul Ricci, Former Chairman and CEO of Nuance Communications
Introduction by: Cathy Minehan
  • Managing Director, Arlington Advisory Partners; Chairman, Board of Trustees, MGH
Moderator: James Brink, MD
  • Chief, Department of Radiology, MGH; Juan M. Taveras Professor of Radiology, HMS
Paul Ricci
  • Former Chairman and CEO, Nuance Communications
1:00 pm – 1:10 pm
Transition to plenary sessions
1:10 pm – 2:00 pm
NVIDIA Ballroom
AI and Gene Sequencing

Gene sequencing technology has evolved considerably over the last 10 years, dramatically decreasing the cost to sequence a human genome. As the costs associated with the technical assay continue to decrease, data interpretation and reporting has become the new bottleneck. Can AI and ML based approaches be applied to better understand how genetic mutations play a role in diseases like cancer – where the high rate of mutation makes treatment challenging? And will continued democratization of genetic information help to accelerate the pace of innovation in the field?

Moderator: Heidi Rehm, PhD
  • Chief Laboratory Director, Laboratory for Molecular Medicine, PHS Personalized Medicine; Associate Professor of Pathology, BWH and HMS
Sandy Farmer, PhD
  • Executive Director, Worldwide R&D, Pfizer
Gad Getz, PhD
  • Director, Bioinformatics Program, Cancer Center and Department of Pathology, MGH; Director, Institute Member, Broad Institute; Associate Professor of Pathology, HMS
Long Le, MD, PhD
  • Director, Computational Pathology and Director, Technology Development, Center for Integrated Diagnostics, MGH; Assistant Professor, Pathology, HMS
Gabriel Otte
  • CEO, Freenome
Susan Tousi
  • SVP, Product Development, Illumina, Inc.
2:00 pm – 2:50 pm
NVIDIA Ballroom
Tangible Returns on the AI Value Proposition

Fueled by billions in venture investments, hundreds of new companies have emerged worldwide to develop and apply AI in health care. Beyond the US, China’s high AI priority has resulted in a vast array of technology driven start-ups. Global investors will discuss which area of machine learning will have the earliest meaningful impact? How do investors critically assess differentiation in such a crowded field? How are investment priorities set among the many divergent categories where AI will take hold?

Moderator: Meg Tirrell
  • Reporter, CNBC
Joe Cunningham, MD
  • Managing Director, Santé Ventures
Roger Kitterman
  • VP, Venture, Innovation, PHS
Amir Nashat, PhD
  • Partner, Polaris Partners
Vijay Pande, PhD
  • Partner, Andreessen Horowitz
Lei Yang, PhD
  • Managing Director, Northern Light Venture Capital
2:50 pm – 3:40 pm
NVIDIA Ballroom
CEO Roundtable: The AI Opportunity as Foundational Change

Chief executives share perspectives on the impact of AI on their respective companies and industry segments. How prominently does AI figure into current investment strategies? And how are they measuring return on existing investments in AI? Panelist will be asked to take a position on whether AI is a truly transformational technology.

Moderator: Peter Slavin, MD
  • President, MGH
Terri Bresenham
  • Chief Innovation Officer, GE Healthcare
Frans van Houten
  • CEO, Philips
Jeffrey Leiden, MD, PhD
  • CEO, Vertex
Bernd Montag, PhD
  • CEO, Siemens Healthineers
3:40 pm – 3:50 pm
NVIDIA Ballroom
Announcement of IDG Awardees
Giles Boland, MD
  • Chair, Department of Radiology, BWH; Philip H. Cook Professor of Radiology, HMS
James Brink, MD
  • Chief, Department of Radiology, MGH; Juan M. Taveras Professor of Radiology, HMS
3:50 pm – 4:40 pm
NVIDIA Ballroom
Regulating AI in Healthcare, Requirements and Challenges

The increasing application of AI in health products puts pressure on the historical model of regulation – among them the agile development cycles and continuous learning environment that support AI / machine learning based algorithms. Panelists will discuss the regulatory approaches including the FDA’s recently announced Software Precertification pilot program.

Moderator: Michael Jaff, DO
  • President, NWH, PHS, Professor of Medicine, HMS
Fabien Beckers, PhD
  • CEO, Arterys
Hilary Malone, PhD
  • Chief Regulatory Officer, Sanofi
Todd McNitt
  • VP and GM, Healthcare Digital Solutions, GE Healthcare
Bakul Patel
  • Associate Director for Digital Health, FDA
4:40 pm – 5:30 pm
NVIDIA Ballroom
AI in Hospital Environments: The Learning Provider

Health systems are actively evaluating strategies to drive efficiency throughout hospital operations. The deployment of AI based technologies to automate organizational tasks (e.g. medical coding / billing, prior authorizations) and optimize resource utilization (e.g. smart scheduling, no-show prediction) promises to help hospital systems adapt to changing macro-economic factors. This panel will discuss the role of AI in hospital operations and assess various approaches to reduce healthcare administration costs and increase efficiency.

Moderator: Adam Landman, MD
  • VP and CIO, Brigham Health
Samuel Aronson
  • Executive Director, IT, Personalized Medicine, PHS
A.G. Breitenstein
  • Partner, Optum Ventures
Neil de Crescenzo
  • CEO, Change Healthcare
Mudit Garg, MD
  • CEO, Qventus
Lisa Maki
  • Co-Founder, Director, PokitDok
5:30 pm – 6:30 pm
GE Foyer
Attendee Networking Reception

Wednesday, April 25, 2018

7:00 am – 7:30 am
Nuance Foyer
Continental Breakfast
7:30 am – 8:20 am
NVIDIA Ballroom
Reconceiving Medical Devices in an AI Dominated Environment

Medical device companies are focused on developing smaller, faster and smarter devices. New technologies will enhance the function of medical devices throughout patient care. Leveraging AI technology to more effectively interact with patients and inform / facilitate outcomes enables smart devices that can learn and improve performance over time. The nature of AI panel based devices, the challenges inherent in developing them and how such devices can evolve over the next 5 years and beyond will be examined.

Moderator: Pat Fortune, PhD
  • VP, Market Sectors, Innovation, PHS
Charles Cadieu, PhD
  • CEO, Bay Labs
Richard Kuntz, MD
  • SVP, Chief Medical and Scientific Officer, Medtronic
Jonathan Rothberg, PhD
  • Founder and CEO, Butterfly Network
Jagmeet Singh, MD, PhD
  • Associate Chief, Cardiology Division, MGH; Professor of Medicine, HMS
8:20 am – 8:50 am
NVIDIA Ballroom
Fireside Chat: Seema Verma, Administrator, Centers for Medicare and Medicaid Services
Moderator: Gregg Meyer, MD
  • Chief Clinical Officer, PHS; Professor of Medicine, HMS; 2018 Forum Co-Chair
Seema Verma
  • Administrator, Centers for Medicare and Medicaid Services
8:50 am – 9:20 am
NVIDIA Ballroom
Fireside Chat: Paying for AI: Thinking Strategically About Reimbursements and Acceptance

Understanding how AI will be absorbed into a highly defined payment system is crucial to determining the rate and breadth that the technology will play in health care in the next decade. Two senior leaders will share their perspectives on how the technology will be paid for and what mechanisms will be used to arbitrate the scope and timing of those payments.

Moderator: Peter Markell
  • EVP Administration and Finance, CFO and Treasurer, PHS
Patrick Conway, MD
  • CEO, BCBS of North Carolina
Eric Murphy
  • CEO, OptumInsight & Enterprise Growth Officer, Optum
9:20 am – 9:50 am
NVIDIA Ballroom
1:1 Fireside Chat: Vasant Narasimhan, MD, CEO, Novartis
Moderator: Gregg Meyer, MD
  • Chief Clinical Officer, PHS; Professor of Medicine, HMS; 2018 Forum Co-Chair
Vasant Narasimhan, MD
  • CEO, Novartis
9:50 am – 10:40 am
NVIDIA Ballroom
Machine Learning in Image Analysis: A Diagnostician’s Best Friend…or Replacement?

Diagnostic imaging is among the clinical fields receiving the greatest attention in the early stages of AI in healthcare. Even in this initial phase it appears that the technology may have profound effects on one of the most resource intensive fields in medicine. Panelists will consider the broad implications as well as topics such as how will role of radiologists evolve? Will AI tools ever become advanced enough to make decisions autonomously within the clinical workflow?

Moderator: Giles Boland, MD
  • Chair, Department of Radiology, BWH; Philip H. Cook Professor of Radiology, HMS
Andrew Beck, MD, PhD
  • CEO, PathAI
Dorin Comaniciu, PhD
  • VP, Medical Imaging Technology, Siemens Healthineers
Eyal Gura
  • Co-Founder and Chairman, Zebra Medical Vision
Karim Karti
  • CEO, GE Healthcare Imaging
Constance Lehman, MD, PhD
  • Chief, Breast Imaging Division, MGH; Professor of Radiology, HMS
10:40 am – 10:50 am
Nuance Foyer
Morning Break
10:50 am – 11:20 am
NVIDIA Ballroom
1:1 Fireside Chat: John Kelly, PhD, SVP, Cognitive Solutions and Research, IBM
Moderator: James Noga
  • VP and CIO, PHS
John Kelly, PhD
  • SVP, Cognitive Solutions and Research, IBM
11:20 am – 12:10 pm
NVIDIA Ballroom
Illuminating the Path to Clinician Empowerment

The sacred exchange between patient and clinician at the heart of medicine is increasingly under duress driven by a range of factors. Increasing clinician burnout is recognized as among the many negative consequences of this trend. Panelists will discuss how AI may improve the quality of the patient encounter, clinician workflow and ultimately clinician quality of life. Panelist will discuss how the new technology can meet these objectives when earlier information based technologies may have exacerbated the challenge.

Moderator: Sree Chaguturu, MD
  • VP, Population Health Management, PHS
Peter Durlach
  • SVP, New Business Development, Healthcare Division, Nuance
Dennis Schmuland, MD
  • Chief Health Strategy Officer, US Health & Life Sciences, Microsoft
Punit Soni
  • CEO, Robin AI
David Ting, MD
  • Chief Medical Information Officer, MGPO
12:10 pm – 1:10 pm
NVIDIA Ballroom
Disruptive Dozen: 12 AI Technologies That Will Reinvent Care

The culture of innovation throughout Partners HealthCare naturally fosters robust discussions about new “disruptive” technologies and which ones will have the biggest impact on health care. The Disruptive Dozen was created to identify and rank the technologies that Partners faculty feel will break through over the next decade to significantly improve health care. This year, the Disruptive Dozen focuses on relevant advances and opportunities in artificial intelligence (AI).

Moderator: Katherine Andriole, PhD
  • Director of Research Strategy and Operations, MGH & BWH CCDS; Associate Professor, Radiology, HMS
Moderator: Keith Dreyer, DO, PhD
  • Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS
1:10 pm – 1:15 pm
NVIDIA Ballroom
Last Look
Keith Dreyer, DO, PhD
  • Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS
Anne Klibanski, MD
  • Chief Academic Officer, PHS; Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, HMS; 2018 Forum Co-Chair
Gregg Meyer, MD
  • Chief Clinical Officer, PHS; Professor of Medicine, HMS; 2018 Forum Co-Chair

*Panels and speakers are subject to change.

Highlighted Presenters

Jensen Huang

CEO, NVIDIA

Vasant Narasimhan MD

CEO, Novartis

Paul Ricci

Former Chairman and CEO, Nuance Communications

Atul Gawande MD

Executive Director, Ariadne Labs; Samuel O. Thier Professor of Surgery, HMS; Surgeon, BWH

Seema Verma

Administrator, Centers for Medicare and Medicaid Services

Sue Siegel

CIO and CEO, Business Innovations, GE

Jeffrey Leiden MD, PhD

CEO, Vertex

Frans van Houten

CEO, Philips

Bernd Montag PhD

CEO, Siemens Healthineers

Terri Bresenham

Chief Innovation Officer, GE Healthcare

John Kelly PhD

SVP, Cognitive Solutions and Research, IBM

Karim Karti

CEO, GE Healthcare Imaging

Jonathan Rothberg PhD

Founder and CEO, Butterfly Network

Jay Bradner MD

President, Novartis Institutes for Biomedical Research

Colin Hill

CEO, GNS Healthcare

Amy Abernethy MD, PhD

CMO, CSO & SVP Oncology, Flatiron Health

Thomas Lynch MD

EVP and CSO, R&D, Bristol-Myers Squibb

Diana Nole

CEO, Wolters Kluwer Health

Roy Beveridge MD

SVP and CMO, Humana

Fabien Beckers PhD

CEO, Arterys

Peter Orszag PhD

Vice Chairman, Investment Banking and Managing Director, Lazard Freres

Georgia Papathomas PhD

SVP, Global Head of Data Sciences, Johnson & Johnson

Punit Soni

CEO, Robin AI

Dan Burton

CEO, Health Catalyst

Jean-François Formela MD

Partner, Atlas Venture

Patrick Conway MD

CEO, BCBS of North Carolina

Jackie Hunter PhD

CEO, BenevolentAI

Greg Moore MD, PhD

VP, Healthcare, Google Cloud

Noga Leviner

CEO, Picnic Health

Leonard D’Avolio PhD

CEO, Cyft, Inc.

Vijay Pande PhD

Partner, Andreessen Horowitz

Iain Buchan MD

‎Director of Healthcare Research, Microsoft Research

Mark Murcko PhD

CSO, Relay Therapeutics

Andrew Hopkins

CEO, Exscientia

Gabriel Otte

CEO, Freenome

David Torchiana MD

CEO, PHS

Joseph Scheeren PharmD

Senior Advisor, R&D, Bayer

Susan Tousi

SVP, Product Development, Illumina, Inc.

Lisa Maki

Co-Founder, Director, PokitDok

Timothy Tuttle PhD

CTO, Cognitive Collaboration Group, Cisco

Seth Hain

Director, Analytics & Machine Learning, Epic

Featured Speakers

Note: speakers are subject to change.

Read Full Post »

Tweets by @pharma_BI and @AVIVA1950 for #PMConf at The 13th Annual Personalized Medicine Conference, From Concept to the Clinic, November 14–16, 2017, Joseph B. Martin Conference Center, Harvard Medical School

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Conference Coverage with Social Media, Patient Experience: Personal Memories of Invasive Medical Intervantion, Patient-centered Medicine, Patient’s Voice: Personal Experience with Invasive Medical Procedures, Personalized and Precision Medicine & Genomic Research, Scientific & Biotech Conferences: Press Coverage on November 17, 2017| Leave a Comment »

Tweets by @pharma_BI and @AVIVA1950 for #PMConf  at The 13th Annual Personalized Medicine Conference, From Concept to the Clinic, November 14–16, 2017, Joseph B. Martin Conference Center, Harvard Medical School, 77 Avenue Louis Pasteur Boston, MA 02115

Curator: Aviva Lev-Ari, PhD, RN

 

@pharma_BI

@AVIVA1950

 

All TWEETS from LPBI’s Twitter.com handles at #PMConf 

@pharma_BI

@AVIVA1950

  2. 0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  3.  17h17 hours ago

    More

    Aviva Lev-Ari Retweeted Gary An

    nice comment

    Aviva Lev-Ari added,

    Replying to @AVIVA1950 @LauraHRussell @Pharma_BI
    This can only work with high-quality, mechanisitic/quasi-mechanistic dynamic models, not -omics, not data-centric. Need to allocate research resources to develop methods to reconcile individual trajectories vs population effects.
    1 reply0 retweets1 like
    Reply

    1

    Retweet

    Like

    1

    View Tweet activity

  4.  18h18 hours ago

    More

    LIVE Day Two – 13th Annual Personalized Medicine, From Concept to the Clinic, November 14–16, 2017, … via

    https://twitter.com/i/cards/tfw/v1/931259383308206080?cardname=summary&autoplay_disabled=true&forward=true&earned=true&edge=true&lang=en&card_height=130&scribe_context=%7B%22client%22%3A%22web%22%2C%22page%22%3A%22me%22%2C%22section%22%3A%22profile%22%2C%22component%22%3A%22tweet%22%7D&bearer_token=AAAAAAAAAAAAAAAAAAAAAPYXBAAAAAAACLXUNDekMxqa8h%252F40K4moUkGsoc%253DTYfbDKbT3jJPCEVnMYqilB28NHfOPqkca3qaAxGfsyKCs0wRbw#xdm_e=https%3A%2F%2Ftwitter.com&xdm_c=default8357&xdm_p=1
    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  5.  19h19 hours ago

    More

    Narrative plan unsupported by facts

    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  6.  19h19 hours ago

    More

    Robert C. Green, M.D., M.P.H., Director, Genomes2People Research Program, Professor of Medicine (Genetics), Brigham and Women’s Hospital, Broad Institute and Harvard Medical School pharmacogenomics can harm if odds are so low adherence will be lower

    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  7.  19h19 hours ago

    More

    Michael Snyder, Ph.D., Stanford W. Ascherman Professor, Chair, Department of Genetics, Director, Center of GenomiPersonalized Medicine, Stanford University School of Medicine Personal sequencing for multiple etiologies rich people are sequenced

    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  8.  19h19 hours ago

    More

    Tom Miller, M.S., Founder, Managing Partner, GreyBird Ventures LLC duty to call up therapies that will not work, balance addressed by PM – diagnostics in PM clinical utility from patient selection for the therapy the patient will respond to

    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  9.  19h19 hours ago

    More

    Sandro Galea, M.D., School of Public Health, Boston University US expense on Health care the highest in the World comes on the expense of housings, mental health, education – curative vs preventive care MDs are insentiviced to keep patients sick

    0 replies1 retweet1 like
    Reply
    Retweet

    1

    Like

    1

    View Tweet activity

  10.  19h19 hours ago

    More

    Robert C. Green, M.D., Broad Institute and HMS Platinum vs gold standard 59 genes will identify 80,000 will get the disease and 47,000 will never get the disease, is the technology the reason for investment vs Family history?

    0 replies1 retweet1 like
    Reply
    Retweet

    1

    Like

    1

    View Tweet activity

  11.  20h20 hours ago

    More

    Bryce Olson, Global Marketing Director, Health and Life Sciences Group, Intel Corporation Genome sequencing found his Pi3K Pathway – PIK3CA p.E54 – Anti Inhibitor for Pi3K = Precision Medicine

    0 replies0 retweets2 likes
    Reply
    Retweet

    Like

    2

    View Tweet activity

  12.  20h20 hours ago

    More

    Sean Khozin, M.D., M.P.H., Associate Director (Acting), Oncology Center of Excellence, FDA 21st Century – metastatic solid tumors – 900 patients: accommodated plan Lab developed Tests: new approach Efficiency, transparency

    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  13.  20h20 hours ago

    More

    innovation INFORMS at NIH Center of Excellence – data collection and analysis of multiple data types Biometric sensors collecting data on cancer patients collaboration with Academia, single arm vs randomized decentralized devices are collecting data

    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  14.  20h20 hours ago

    More

    FDA considers N of One, small samples, EGFR drug was approved in 2 1/2 years since Phase 1 of NDA New trial designs: reduce bias and alternative end points narrow criteria for participation, more personalized and more patient-centered innovation

    1 reply2 retweets2 likes
    Reply

    1

    Retweet

    2

    Like

    2

    View Tweet activity

  15.  20h20 hours ago

    More

    Sean Khozin, M.D., M.P.H., Associate Director (Acting), Oncology Center of Excellence, FDA Advances of technology of biomarkers, disease indication Accelerated approval by FDA a collaborative of speeding the process companion diagnosis assays

    0 replies2 retweets1 like
    Reply
    Retweet

    2

    Like

    1

    View Tweet activity

  16.  21h21 hours ago

    More

    Unmet need, commitment is there, innovation and connectivity drive access, collaboration not competition – helps Precision medicine in emerging nations. Access to PM anywhere in the world suggested Kristin Pothier, MS, Global Head, Life Sciences EY

    0 replies1 retweet1 like
    Reply
    Retweet

    1

    Like

    1

    View Tweet activity

  17.  24h24 hours ago

    More

    Stephen L. Eck, M.D., Ph.D., President, CEO, Aravive Biologics; Board Chairman, PMC Laxo – A molecular target to be found by diagnostics TEST — as a basis to develop a drug Pricing and value – dimensions of Value to society How PM is done today?

    0 replies1 retweet1 like
    Reply
    Retweet

    1

    Like

    1

    View Tweet activity

  18.  24h24 hours ago

    More

    Marc S. Williams, MD Geisinger Clinical Genomics vs Physician specialist (i.e.,hypercholestoralemia), both in same place – paper and EMR Outcomes – tracking patients over decades – systems in place to capture the data Virtual Cycle Clinical data

    0 replies1 retweet1 like
    Reply
    Retweet

    1

    Like

    1

    View Tweet activity

  19.  24h24 hours ago

    More

    Timothy Cannon, M.D., Inova Molecular Tumor Board, 5 hospital in VA, Precision Genomics Cancer Therapy Poor understanding of molecular results by MDs, Refractory Patients no Forum to discuss other options 220 patients presented beyond InovaOncologi

    0 replies1 retweet1 like
    Reply
    Retweet

    1

    Like

    1

    View Tweet activity

  20.  Nov 16

    More

    Scott A. Beck, Mayo Clinic, MN, AZ PM, Genomics sequencing, BioEthics, IT, Translational Perspective in Epi-genomics, Discovery to Translation Applicattions Pharmacy- Formulary – EMR – Champions from Disease areas to practice environment Testing

    0 replies3 retweets3 likes
    Reply
    Retweet

    3

    Like

    3

    View Tweet activity

  21.  Nov 16

    More

    payment dominates delivery of care, future PM from Genomics cost to patients Transform acceptability of PM suggested Ronald A. Paulus, M.D., M.B.A., President, CEO, Mission Health, NC, ex-Geisinger, CIO

    0 replies1 retweet1 like
    Reply
    Retweet

    1

    Like

    1

    View Tweet activity

  22.  Nov 16

    More

    Genomics based PM to be turned into Wellness Strategy – the path not yet knows said Jeffrey R. Balser, M.D., Ph.D., Dean, Vanderbilt University School of Medicine; President, CEO, Vanderbilt University Medical Center, Nashville, TN

    0 replies1 retweet1 like
    Reply
    Retweet

    1

    Like

    1

    View Tweet activity

  23.  Nov 16

    More

    Millianlian Diabetics NOT on Medicare, Analytics: iPhone telling patient dishes to order since SYSTEM KNOWS BLOOD SUGER 24×7 – target care by Analytics Genomics paid by NIH PM Analytics is built at Vanderbilt University MC, Jeffrey R. Balser, CEO

    0 replies1 retweet1 like
    Reply
    Retweet

    1

    Like

    1

    View Tweet activity

  24.  Nov 15

    More

    LIVE Day One – 13th Annual Personalized Medicine, From Concept to the Clinic, November 14–16, 2017, … via

    https://twitter.com/i/cards/tfw/v1/930919823843962890?cardname=summary&autoplay_disabled=true&forward=true&earned=true&edge=true&lang=en&card_height=130&scribe_context=%7B%22client%22%3A%22web%22%2C%22page%22%3A%22me%22%2C%22section%22%3A%22profile%22%2C%22component%22%3A%22tweet%22%7D&bearer_token=AAAAAAAAAAAAAAAAAAAAAPYXBAAAAAAACLXUNDekMxqa8h%252F40K4moUkGsoc%253DTYfbDKbT3jJPCEVnMYqilB28NHfOPqkca3qaAxGfsyKCs0wRbw#xdm_e=https%3A%2F%2Ftwitter.com&xdm_c=default8358&xdm_p=1
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  25.  Nov 15

    More

    Survival of patient with mutation and targeted drug LIVE LONGER David B. Roth, M.D., Ph.D., Simon Flexner Professor Chair, Pathology and Laboratory Medicine, Perelman School of Medicine at University of Pennsylvania

    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  26.  Nov 15

    More

    Lotte Steuten, Ph.D., School of Pharmacy at University of Washington, Seattle aggregate big data , models as evidence, has value to clinical, the model under development NGS Profile of Patient vs current standard of care.

    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  27.  Nov 15

    More

    David B. Roth, M.D., Ph.D., UPenn Director, Penn Center for Precision Medicine 5000 patients underwent genome sequencing Interpretation is the issue that is hard Health IT are still in silos: Pharmacy data, financial data, EMR

    0 replies0 retweets2 likes
    Reply
    Retweet

    Like

    2

    View Tweet activity

  28.  Nov 15

    More

    Michael Pellini, M.D., M.B.A., Chairman, Board of Directors, Foundation Medicine; Board Member, Personalized Medicine Coalition, we know there is value in PM we need to work together on the challenges — to prove the value in PM

    0 replies1 retweet1 like
    Reply
    Retweet

    1

    Like

    1

    View Tweet activity

  29.  Nov 15

    More

    Andrea Stern Ferris, M.B.A., President, Chairman of the Board, LUNGevity Foundation – PATIENT to be included in the conversation patient after successful treatment have hope work pay taxes pay to health plans continue family life

    0 replies1 retweet1 like
    Reply
    Retweet

    1

    Like

    1

    View Tweet activity

  30.  Nov 15

    More

    Molecular Era, NEJM, 2017, 377, 1813-1823, BRAF in Melanoma – 80% do not need additional therapy vs 20% benefitted in the Non-Molecular Era, data by Dane J. Dickson, CureOne (formerly MED-C); Oregon Health and Science University

    0 replies1 retweet4 likes
    Reply
    Retweet

    1

    Like

    4

    View Tweet activity

  31.  Nov 15

    More

    CURES – CAR-T are they cures??? A teen-ager’s Value-based Price: $475,000 x years lived suggests  Steven D. Pearson, M.D., M.Sc., Founder, President, Institute for Clinical and Economic Review (ICER)

    0 replies1 retweet1 like
    Reply
    Retweet

    1

    Like

    1

    View Tweet activity

  32.  Nov 15

    More

    Of 134 drugs in development – 42 have the potential to become Personalized medicine therapies, said Stephen J. Ubl, President, CEO, PhRMA

    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  33.  Nov 15

    More

    Transplantation vs enhancement – resistance to senescence and pathogens to be achieved by gene editing suggests George M. Church, Ph.D., Professor of Genetics

    0 replies0 retweets2 likes
    Reply
    Retweet

    Like

    2

    View Tweet activity

  34.  Nov 15

    More

    Regulatory oversight on engineering embrios is coming, metric of success in recruitment of patients said Arthur L. Caplan, Ph.D., Drs. William F. and Virginia Connolly Mitty Chair, Director, Division of Medical Ethics, New York Univ

    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  35.  Nov 15

    More

    CRISPR does not handle all mutation many require a different editing tool said George M. Church, Ph.D., Professor of Genetics, Health Sciences and Technology, Harvard-MIT Division of Health Sciences and Technology

    0 replies0 retweets2 likes
    Reply
    Retweet

    Like

    2

    View Tweet activity

  36.  Nov 15

    More

    understand well enough  the gentic application where CRISPR will assist medicine: Retinal degeneration, two aspects one worked in Japan said Katrine Bosley, CEO, Editas Medicine

    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  37.  Nov 15

    More

    Aviva Lev-Ari Retweeted Aviva Lev-Ari

    Amazing Power in hands of informed patients

    Aviva Lev-Ari added,

    Patients input and sophistication increased – IRB is not aware of the engagement of Patients and their challenging feedback say Deborah Schrag, M.D., M.P.H, Dana Farber
    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  38.  Nov 15

    More

    Patients input and sophistication increased – IRB is not aware of the engagement of Patients and their challenging feedback say Deborah Schrag, M.D., M.P.H, Dana Farber

    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  39.  Nov 15

    More

    Physicians needs interfaces, dashboard information delivered to MDs, data sits unused, new tools are needed for the data display by relevance to the MDs – clinicians needs decision support in their office

    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  40.  Nov 15

    More

    Standards: Toxicity criteria – library of 882 symptoms, Patient reported outcomes by Patients, Resist criteria applied to imaging data criteria for brain tumors said Deborah Schrag, M.D., M.P.H., Chief Medical Oncology, Dana-Farber

    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  41.  Nov 15

    More

    drafting document on Verify data integrity in clinical trials, detect discrepancies compromise the integrity of the data – audits by FDA said Sean Khozin, M.D., M.P.H., Associate Director (Acting), Oncology Center of Excellence, FDA

    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  42.  Nov 15

    More

    pre-existing autoimmune disease – not indicated for them Immunotherapy even though patients wish to try said Deborah Schrag, M.D., M.P.H., Chief, Division of Population Sciences, Medical Oncology, Dana-Farber Cancer Institute

    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  43.  Nov 15

    More

    Drug approved for one indication, provide new data for supplemental indications said Sean Khozin, M.D., M.P.H., Associate Director (Acting), Oncology Center of Excellence, FDA

    0 replies0 retweets3 likes
    Reply
    Retweet

    Like

    3

    View Tweet activity

  44.  Nov 15

    More

    Eric G. Klein, Pharm.D, Eli Lilly Aggregate burden of disease, existence of co-morbidities Genomics: WHY is explained – precise tools data vs intelligence – interoperability Past clinical trial, replicate studies retrospective data

    0 replies1 retweet2 likes
    Reply
    Retweet

    1

    Like

    2

    View Tweet activity

  45.  Nov 15

    More

    linkages vs computational techniques we do not have consistent data, data structured Vital sign or WBC count – we have data standardization is evolving said Deborah Schrag, M.D., M.P.H., Chief, Dana-Farber Cancer Institute

    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  46.  Nov 15

    More

    use data sets prospective vs retrospective studies asked Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Flatiron Health; Board Member, Personalized Medicine Coalition

    0 replies2 retweets1 like
    Reply
    Retweet

    2

    Like

    1

    View Tweet activity

  47.  Nov 15

    More

    Clinical sense vs research context, FDA is more comfortable with other than oncology products beyond drugs, namely diagnostics, diagnostics company seeking partnership with many drug areas Thermo FIscher and Novartis partnership

    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  48.  Nov 15

    More

    Cost of CT Scan vs an NGS Test – Genomic testing is much cheaper yet volume is still low said Jacob S. Van Naarden, Chief Business Officer, Loxo Oncology

    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  49.  Nov 15

    More

    NGS – time results come back what the mutation mean? NOW results come in few days, data analysis assist the said Joydeep Goswami, Ph.D., M.B.A., M.S., President, Clinical Next-Generation Sequencing, Oncology, Thermo Fisher Scientifi

    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  50.  Nov 15

    More

    3D BioPrinting of Drugs and the innovation storm of agents — are both benefits, value based pricing, elasticities, is that price sufficient to support R&D, dynamic environment said Joshua Ofman, SVP, Global Value, Access, Amgen

    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  51.  Nov 15

    More

    Awardee of Leadership in PM, Illumina, HC system not yet ready for Precision Medicine

    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  52.  Nov 15

    More

    Amgen and Harvard Pilgrims interpretation of Values related to partnerships: Novartis

    0 replies0 retweets1 like
    Reply
    Retweet

    Like

    1

    View Tweet activity

  53.  Nov 15

    More

    at Illimina – Consumer Advocacy added to Technology breakthroughs in genome sequencing said Jay T. Flatley, M.S., Executive Chairman, Illumina

    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  54.  Nov 15

    More

    National Genomic Service – Sequencing becoming STANDARD of Care, phynotypes, $10 million to be spent NIH said Jay T. Flatley, M.S., Executive Chairman, Illumina

    0 replies0 retweets0 likes
    Reply
    Retweet

    Like

    View Tweet activity

  55.  Nov 15

    More

    13th Annual Leadership in Personalized Medicine Award AWARDEE | Jay T. Flatley, M.S., Executive Chairman, Illumina

    0 replies1 retweet0 likes
    Reply
    Retweet

    1

    Like

    View Tweet activity

  56.  Nov 15

    More

    13th Annual Leadership in PM Award to Jay T Flatlet, Illumina

Read Full Post »

LIVE Day Two – 13th Annual Personalized Medicine Conference, From Concept to the Clinic, November 14–16, 2017, Joseph B. Martin Conference Center, Harvard Medical School, 77 Avenue Louis Pasteur Boston, MA 02115

Posted in Conference Coverage with Social Media, Personalized and Precision Medicine & Genomic Research, Scientific & Biotech Conferences: Press Coverage on November 16, 2017| Leave a Comment »

LIVE Day Two – 13th Annual Personalized Medicine Conference, From Concept to the Clinic, November 14–16, 2017, Joseph B. Martin Conference Center, Harvard Medical School, 77 Avenue Louis Pasteur Boston, MA 02115

 

JOSEPH B. MARTIN CONFERENCE CENTER

HARVARD MEDICAL SCHOOL, BOSTON, MA 02115

http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/13th_Annual_PM_Conference37.pdf

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

pharma_bi-background0238

will cover in REAL TIME the 13th Annual Personalized Medicine, From Concept to the Clinic, November 14–16, 2017, Joseph B. Martin Conference Center, Harvard Medical School, 77 Avenue Louis Pasteur Boston, MA 02115

In attendance, covering LIVE using Social Media

Aviva Lev-Ari, PhD, RN

Editor-in-Chief

http://pharmaceuticalintelligence.com

@pharma_BI

@AVIVA1950

#PMConf

Agenda · Part II  NOVEMBER 16, 2017 · CONFERENCE PROGRAM | AGENDA

7:00 am Registration and Breakfast

8:00 am Opening Remarks

SPEAKER | Stephen L. Eck, M.D., Ph.D., President, CEO, Aravive Biologics; Board Chairman, Personalized Medicine Coalition

  • 2005 at Pfizer new initiative on Personalized Medicine
  • Left to go to Lilly – not to give a drug to  Patients with KRAS mutation – beginning of PM
  • Laxo – A molecular target to be found by diagnostics TEST  — as a basis to develop a drug
  • Pricing and value – dimensions of Value to society
  • How PM is done today

8:10 am Clinical Adoption of Personalized Medicine: A Two-Part Discussion Pioneering health care providers have begun to explore the business models, operational processes, IT infrastructure and educational programs that are needed to catalyze the paradigm shift toward personalized medicine. This two-part session on clinical adoption will examine the strategic and day-to-day challenges clinical organizations face as they seek to integrate personalized medicine in clinical settings — and the solutions they employ to address those challenges.

SESSION CHAIR | Marcia A. Kean, M.B.A., Chairman, Strategic Initiatives, Feinstein Kean Healthcare

Discussion Part 1

8:15 am The Case for Personalized Medicine in the Clinic: The View From the Corner Office Inspiring an organizational commitment to a new way of practicing medicine requires visionary leadership. This fireside chat will highlight the viewpoints and approaches of leaders who are spearheading efforts to adopt personalized medicine at clinical institutions, with an eye on the value proposition for changing existing norms and practices.

MODERATOR | Howard L. McLeod, Pharm.D., Medical Director, The DeBartolo Family Personalized Medicine Institute, Chair, Department of Individualized Cancer Management, Senior Member, Division of Population Sciences, Moffitt Cancer Center; Board Member, Personalized Medicine Coalition

Jeffrey R. Balser, M.D., Ph.D., Dean, Vanderbilt University School of Medicine; President, CEO, Vanderbilt University Medical Center, Nashville, TN

  • Vanderbilt University Medical Center [$500 Million in Grants] is a HealthCare System, split from Vanderbilt University School of Medicine [1200 Medical Residents], now they are like Partners
  • BioMedical Informatics very strong at Vanderbilt University School of Medicine
  • Jeffrey R. Balser, M.D., Ph.D. was first student of Dan, A pioneer in Personalized Medicine
  • PM and Non-Oncology: PLAVIX – DSS when MD order drugs DSS trigger No PLAVIX to this patient, made second decision in real time by MDs
  • Nashville – four flagship hospitals, largest HMO not for profit in the country
  • PM at Vanderbilt University Medical Center – 25 drugs – given ONLY after Genomic sequencing
  • Millianlian Diabetics NOT on Medicare, Analytics: iPhone telling patient what dishes to order since SYSTEM KNOWS BLOOD SUGER 24×7 – target care by Analytics
  • Genomics paid by NIH
  • PM Analytics is built at Vanderbilt University Medical Center said Jeffrey R. Balser, M.D., Ph.D., Dean, Vanderbilt University School of Medicine; President, CEO, Vanderbilt University Medical Center
  • what is the economics benefit of Genomic sequencing: DSS on Drugs – Peterson is documenting drug class by economic benefit – bundle to show value
  • Genomics based PM is on drugs — polimorthism – this drug will not work
  • Disease counseling is harder than drug = wellness strategy is the Fututre
  • Genomics based PM to be turned into Wellness Strategy – the path not yet knows said Jeffrey R. Balser, M.D., Ph.D., Dean, Vanderbilt University School of Medicine; President, CEO, Vanderbilt University Medical Center, Nashville, TN
  • Research Investment is R&D, decisions made to guide all research and investment in PM initiative – not generating money. Pilot studies leads to grants. One study is on Economic benefit of PM

Ronald A. Paulus, M.D., M.B.A., President, CEO, Mission Health, NC, ex-Geisinger, CIO

  • 8 most western counties in NC
  • small group of Genetists:
  1. PM and Oncology and – Cancer therapy from a Genomics stand point
  2. PM and Non-Oncology – Drug-Drug interactions
  3. Clinicians needs actionable information
  4. Primary care practices to adopt PM – HOW, where, why? what will be out of pocket expense to the individual
  5. subsidization is a must
  6. payment dominates delivery of care, future PM from Genomics cost to patients
  7. Transform acceptability of PM suggested Ronald A. Paulus, M.D., M.B.A., President, CEO, Mission Health, NC, ex-Geisinger, CIO

Discussion Part 2

9:00 am Practicing Personalized Medicine: Lessons From the Front Lines To successfully integrate personalized medicine into a health system, administrators and clinicians must also design and implement new processes related to program infrastructure and informatics; help educate physicians and patients about the field; and inspire cultural change within the institution. During this panel discussion, a group of early adopters will share lessons learned from implementing pilot programs across the United States.

MODERATOR | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition

Bonnie J. Addario, Founder, Chair, Bonnie J. Addario Lung Cancer Foundation; Board Member, Personalized Medicine Coalition; Lung Cancer Survivor

Scott A. Beck, M.B.A., Administrator, Center for Individualized Medicine, Mayo Clinic, MN, AZ

  • PM, Genomics sequencing, BioEthics, IT, Translational Perspective in Epi-genomics,
  • Discovery to Translation Applicattions
  • Pharmacy- Formulary – EMR – Champions from Disease areas to practice environment
  • Testing offering, approve value
  • 25 Projects: PharmacoGenomics Testing to patients, change drug before repeat endoscopy

Timothy Cannon, M.D., Clinical Director, Inova Schar Cancer Institute Molecular Tumor Board

  • 5 hospital in VA,
  • Precision Genomics Cancer Therapy
  • Poor understanding of molecular results by MDs, Refractory Patients – no Forum to discuss other options
  • Molecular Tumor Board for Inova Health System: 220 patients presented beyond Inova
  • Oncologists had concerned that patients are aware of drug that MD can’t deliver to client

Peter Hulick, M.D., M.M.Sc., Medical Director, Center for Personalized Medicine, NorthShore University HealthSystem

  • 4 hospitals – 950 MDs
  • PCP to get engaged
  • Neurology
  • Genetic Assessment tool DSS offers PCP option for electronic ordering of the Genetic Testing, Results appear in Patients’ charts
  • Proactive testing
  • 20,000 patients in the system to be tested for pharmaco-genomics testing

Marc S. Williams, M.D., F.A.A.P., F.A.C.M.G., F.A.C.M.I., Director, Genomic Medicine Institute, Geisinger – Central PA

  • 30% of providers are Geisinger the rest are not
  • Genomics: PM — Microbiome bank – broad user consent: recontact and return results
  • Genomics Medicine Institute – 2014 Partnership with Regeneron – genomics sequencing and profiling — all result to be used by Geisinger
  • 170,000 patient consented – 90% responded, 8,000 sequences available
  • 80 gene with potential actionability – interpretation by Scientists
  • Pathologic calls return results –
  • Clinical Genomics vs Physician specialist (i.e.,hypercholestoralemia), both in same place – paper and EMR
  • Outcomes – tracking patients over decades – systems in place to capture the data
  • Virtual Cycle Clinical data – dashboards were created to deliver results per week.
  • 1/2 people do not need criteria
  • Geisinger will disseminate internationally

10:15 am Networking Break (sponsored by Moffitt Cancer Center)

10:45 am Harvard Business School Case Study — Intermountain Healthcare: Pursuing Precision Medicine Intermountain has a long history of being at the forefront of health care quality improvement and the development of treatment protocols. In 2013, Intermountain Precision Genomics (IPG) was started with Dr. Lincoln Nadauld as its Executive Director. IPG focused on stage 4 cancer patients and performed three distinct functions: genomic sequencing, interpretation of sequencing results with recommendations for precision therapies, and drug acquisition and reimbursement. A paper published in February 2017 reported that in addition to having a higher quality of life, patients who received the targeted therapies had progression-free survival rates of almost twice as long as other patients. The purpose of our case discussion will be to assess these efforts, to consider their broader applicability and to review IPG’s plans for the future.

PRESENTER | Richard Hamermesh, D.B.A., Co-Faculty Chair, Harvard Business School Kraft Precision Medicine Accelerator

12:00 pm Overview of the International Landscape for Personalized Medicine

PRESENTER | Kristin Pothier, M.S., Global Head, Life Sciences, Parthenon-EY

  • Precision Medicine in the Globe – stackholder ecosystem
  • India
  • Latin America
  • USA
  • Africa
  • EU
  • APAC
  • Middle East

Regional Spotlight:

China – strength emerging 1.4 Billion people, 4.2 million annual incidence of Cancer – systemic challenges will limit access

Brazil – 440,000 cancer incidents a year, 207 Million Corporate, Hospital, Government, Academic research, collaboration vs competition, collaboration will win

Dubai – 28.5 Million population

Qatar –

UAE – Initiative to sequence the entire population, 6,000 done

Saudi Arabia

Middle East – 0.4 oncologist for 100,000

Summary – Unmet need, commitment is there, innovation and connectivity drive access, collaboration not competition – helps Precision medicine in emerging nations. Access to PM anywhere in the world suggested Kristin Pothier, M.S., Global Head, Life Sciences, Parthenon-EY

12:30 pm Bag Lunch

1:30 pm Personalized Medicine at FDA: An Inside Look at the Agency’s Priorities for the Field

INTRODUCTION | Cynthia A. Bens, Vice President, Public Policy, Personalized Medicine Coalition

KEYNOTE | Sean Khozin, M.D., M.P.H., Associate Director (Acting), Oncology Center of Excellence, FDA

  • Advances of technology of biomarkers, disease indication
  • Accelerated approval by FDA a collaborative of speeding the process
  • companion diagnosis assays and drug or biologics
  • FDA considers N of One, small samples, EGFR drug was approved in 2 1/2 years since Phase 1 of NDA
  • New trial designs: reduce bias and alternative end points
  • narrow criteria for participation, more personalized and more patient-centered
  • innovation INFORMS at NIH Center of Excellence – data collection and analysis of multiple data types
  • Biometric sensors collecting data on cancer patients
  • collaboration with Academia, single arm vs randomized, decentralized
  • devices are collecting data in clinical trials
  • 21st Century – metastatic solid tumors – 900 patients: accommodated plan
  • Lab developed Tests: new approach
  • Efficiency, transparency

2:00 pm The Patient Perspective on Personalized Medicine

INTRODUCTION | Susan McClure, Founder, Publisher, Genome magazine; Board Member, Personalized Medicine Coalition

  • Precision medicine and relevant information for Patients
  • Genomic sequencing is the Opening Gate to PM

KEYNOTE | Bryce Olson, Global Marketing Director, Health and Life Sciences Group, Intel Corporation

  • genome sequencing found his Pi3K Pathway – PIK3CA p.E54 – Anti Inhibitor for Pi3K = Precision Medicine

2:30 pm Patient 2.0: Exploring the Future of Personalized Medicine Many observers speculate that the coming wave of gene editing, gene therapy, direct-to-consumer genetic tests and the personalized use of wearables will change the psychology, sociology, economy and efficacy of health care. Informed by the previous panel discussions, this conversation will examine the future of personalized medicine and the merits of these emerging trends.

MODERATOR | Robert C. Green, M.D., M.P.H., Director, Genomes2People Research Program, Professor of Medicine (Genetics), Brigham and Women’s Hospital, Broad Institute and Harvard Medical School

  • Neurologist first , Geneticist thereafter
  • Platinum vs gold standard
  • 59 genes will identify 80,000 will get the disease and 47,000 will never get the disease
  • is the technology the reason for investment vs Family history
  • pharmacogenomics can harm, if odds are so low than adherence will be lower

Sandro Galea, M.D., M.P.H., Dr.P.H., Dean, Robert A. Knox Professor, School of Public Health, Boston University

  • Skeptical of societal aspects: race, 50% of the country health getting better vs 50% getting worse but enthusiast on technology
  • US expense on Health care the highest in the World comes on the expense of housings, mental health, education – curative vs preventive care
  • MDs are insentiviced to keep patients sick
  • Folic Acid
  • Nudge behavior
  • invest in long livivng

Tom Miller, M.S., Founder, Managing Partner, GreyBird Ventures LLC

  • duty to call up therapies that will not work, balance addressed by PM – diagnostics in PM
  • clinical utility from patient selection for the therapy the patient will respond to
  • fantasy: Medical decision making to be made to avoid un neccesary care

Michael Snyder, Ph.D., Stanford W. Ascherman Professor, Chair, Department of Genetics, Director, Center of Genomics and Personalized Medicine, Stanford University School of Medicine

  • Personal sequencing for multiple etiologies
  • rich people come to get sequenced
  • libraries
  • Providers to be incentivized if patients are health

3:30 pm Closing Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

Read Full Post »

« Newer Posts - Older Posts »